CA2570130C - Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof - Google Patents
Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof Download PDFInfo
- Publication number
- CA2570130C CA2570130C CA2570130A CA2570130A CA2570130C CA 2570130 C CA2570130 C CA 2570130C CA 2570130 A CA2570130 A CA 2570130A CA 2570130 A CA2570130 A CA 2570130A CA 2570130 C CA2570130 C CA 2570130C
- Authority
- CA
- Canada
- Prior art keywords
- protofibrils
- antibody
- protofibril
- beta
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
- G01N2800/385—Congenital anomalies
- G01N2800/387—Down syndrome; Trisomy 18; Trisomy 13
Abstract
The invention pertains to the development of antibodies that specifically bind amyloid beta protein (Abeta) in its protofibril conformation. The invention also comprises methods of using anti-Abeta protofibril antibodies to diagnose or treat Alzheimer's disease, Down's syndrome Lewybody dementia, vascular dementia, and other neurodegenerative disorders. Furthermore, the invention pertains to the use of anti-Abeta protofibril antibodies to screen and identify substances that will modulate protofibril activity or formation in vitro or in vivo. The invention also pertains to methods for synthesising pure Abeta protofibril antigens as well as to a method for stabilising Abeta protofibrils antigens as well as to a method for stabilising Abeta protofibrils.
Description
Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof I. FIELD OF INVENTION
This invention pertains to the diagnosis, prevention and treatment of neurodegenerative diseases, in particular Alzheimer's disease, and other similar disease. More precisely, to antibodies that specifically bind amyloid beta protein (A(3) in its protofibril conformation.
This invention pertains to the diagnosis, prevention and treatment of neurodegenerative diseases, in particular Alzheimer's disease, and other similar disease. More precisely, to antibodies that specifically bind amyloid beta protein (A(3) in its protofibril conformation.
2. BACKGROUND OF THE INVENTION
Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disorder causing cognitive, memory and behavioural impairments. It is the most common cause of dementia in the elderly population affecting roughly 5% of the population above 65 years and 20% above 80 years of age. AD is characterized by an insidious onset and progressive deterioration in multiple cognitive functions. The neuropathology involves both extracellular and intracellular argyrophillic proteineous deposits. The extracellular deposits, referred to as neuritic plaques, mainly consist in amyloid beta protein (AP) surrounded by dystrophic neurites (swollen, distorted neuronal processes). AP within these extracellular deposits are fibrillar in their character with a 3-pleated sheet structure. AP in these deposits can be stained with certain dyes e.g. Congo Red and display a fibrillar ultrastructure.
These characteristics, adopted by AP in its fibrillar structure of neuritic plaques, are the definition of the generic term amyloid. The classic intracellular AD
pathologic lesion is the neurofibrillary tangle (NFT) which consists of filamentous structures called paired helical filaments (PHFs) composed of twisted strands of hyperphosphorylated microtubule-associated protein tau. Frequent neuritic plaques and neurofibrillary tangle deposits in the brain are diagnostic criteria for AD, as carried out post mortem. AD brains also display macroscopic brain atrophy, nerve cell loss, local inflammation (microgliosis and astrocytosis) and often congophilic amyloid angiopathy (CAA) in cerebral vessel walls.
Two forms of Ap peptides, A1340 and AP42, are the dominant species in AD
neuritic plaques (Masters 1985), while A340 is the prominent species in cerebrovascular amyloid associated with AD (Glenner 1984). Enzymatic activities allow AP to be continuously formed from a larger protein called the amyloid precursor protein (APP) in both healthy and AD afflicted subjects in all cells of the body. Two major APP processing events through 13- and y-secretase activities enables Ap production, while a third enzyme called a-secretase activities prevents AP generation by cleavage inside the AP sequence (Selkoe, 1994; US5604102). The A1342 is a forty two amino acid long peptide i.e. two amino acids longer at the C-terminus, as compared to A1340. A1342 is more hydrophobic, and does more easily aggregate into larger structures of Ap peptides such as AP dimers, AP tetramers, AP oligomers, Al3 protofibrils or A13 fibrils. AP fibrils are hydrophobic and insoluble, while the other structures are all less hydrophobic and soluble. All these higher molecular structures of AP peptides are individually defined based on their biophysical and structural appearance e.g. in electron microscopy, and their biochemical characteristics e.g. by analysis with size-exclusion chromatography/western blot.
These AP peptides, particularly A1342, will gradually assemble into a various higher molecular structures of AP during the life span. AD, which is a strongly age-dependent disorder, will occur earlier in life if this assembly process occurs more rapidly. This is the core of the "am.yloid cascade hypothesis" of AD which claims that APP processing, the A1342 levels and their assembly into higher molecular structures is a central cause of AD. All other neuropathology of AD brain and the symptoms of AD such as dementia are somehow caused by Ap or assembled forms thereof.
Ap can exist in different lengths i.e. 1-39,1-40,1-42 and 1-43 and fragments sizes i.e. 1-28, 3-40/42, 11-40/42, 17-40/42 and 25-35. All these peptides can aggregate and form soluble intermediates and insoluble fibrils, each molecular form having a unique structural conformation and biophysical property. Monomeric A31-42 for example, is a 42 amino acid long soluble and non-toxic peptide, that is suggested to be involved in normal synapse functions. Under certain conditions, the A131-42 can aggregate into dimers, trimers, tetramers, pentamers up to 12-mer and higher oligomeric forms, all with its distinct physicochemical property such as molecular size, EM structure and AFM (atomic force microscopy) molecular shape. An example of a higher molecular weight soluble oligomeric AP form is the protofibril (Hartley 1999, Walsh 1999), which has an apparent molecular weight >100 kDa and a curvelinear structure of 4-11 nm in diameter and < 200 nm in length. It has
Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disorder causing cognitive, memory and behavioural impairments. It is the most common cause of dementia in the elderly population affecting roughly 5% of the population above 65 years and 20% above 80 years of age. AD is characterized by an insidious onset and progressive deterioration in multiple cognitive functions. The neuropathology involves both extracellular and intracellular argyrophillic proteineous deposits. The extracellular deposits, referred to as neuritic plaques, mainly consist in amyloid beta protein (AP) surrounded by dystrophic neurites (swollen, distorted neuronal processes). AP within these extracellular deposits are fibrillar in their character with a 3-pleated sheet structure. AP in these deposits can be stained with certain dyes e.g. Congo Red and display a fibrillar ultrastructure.
These characteristics, adopted by AP in its fibrillar structure of neuritic plaques, are the definition of the generic term amyloid. The classic intracellular AD
pathologic lesion is the neurofibrillary tangle (NFT) which consists of filamentous structures called paired helical filaments (PHFs) composed of twisted strands of hyperphosphorylated microtubule-associated protein tau. Frequent neuritic plaques and neurofibrillary tangle deposits in the brain are diagnostic criteria for AD, as carried out post mortem. AD brains also display macroscopic brain atrophy, nerve cell loss, local inflammation (microgliosis and astrocytosis) and often congophilic amyloid angiopathy (CAA) in cerebral vessel walls.
Two forms of Ap peptides, A1340 and AP42, are the dominant species in AD
neuritic plaques (Masters 1985), while A340 is the prominent species in cerebrovascular amyloid associated with AD (Glenner 1984). Enzymatic activities allow AP to be continuously formed from a larger protein called the amyloid precursor protein (APP) in both healthy and AD afflicted subjects in all cells of the body. Two major APP processing events through 13- and y-secretase activities enables Ap production, while a third enzyme called a-secretase activities prevents AP generation by cleavage inside the AP sequence (Selkoe, 1994; US5604102). The A1342 is a forty two amino acid long peptide i.e. two amino acids longer at the C-terminus, as compared to A1340. A1342 is more hydrophobic, and does more easily aggregate into larger structures of Ap peptides such as AP dimers, AP tetramers, AP oligomers, Al3 protofibrils or A13 fibrils. AP fibrils are hydrophobic and insoluble, while the other structures are all less hydrophobic and soluble. All these higher molecular structures of AP peptides are individually defined based on their biophysical and structural appearance e.g. in electron microscopy, and their biochemical characteristics e.g. by analysis with size-exclusion chromatography/western blot.
These AP peptides, particularly A1342, will gradually assemble into a various higher molecular structures of AP during the life span. AD, which is a strongly age-dependent disorder, will occur earlier in life if this assembly process occurs more rapidly. This is the core of the "am.yloid cascade hypothesis" of AD which claims that APP processing, the A1342 levels and their assembly into higher molecular structures is a central cause of AD. All other neuropathology of AD brain and the symptoms of AD such as dementia are somehow caused by Ap or assembled forms thereof.
Ap can exist in different lengths i.e. 1-39,1-40,1-42 and 1-43 and fragments sizes i.e. 1-28, 3-40/42, 11-40/42, 17-40/42 and 25-35. All these peptides can aggregate and form soluble intermediates and insoluble fibrils, each molecular form having a unique structural conformation and biophysical property. Monomeric A31-42 for example, is a 42 amino acid long soluble and non-toxic peptide, that is suggested to be involved in normal synapse functions. Under certain conditions, the A131-42 can aggregate into dimers, trimers, tetramers, pentamers up to 12-mer and higher oligomeric forms, all with its distinct physicochemical property such as molecular size, EM structure and AFM (atomic force microscopy) molecular shape. An example of a higher molecular weight soluble oligomeric AP form is the protofibril (Hartley 1999, Walsh 1999), which has an apparent molecular weight >100 kDa and a curvelinear structure of 4-11 nm in diameter and < 200 nm in length. It has
3 recently been demonstrated that soluble oligomeric A13 peptides such as Ap protofibrils impair long-term potentiation (LTP) (Hartley, 1999), a measure of synaptic plasticity that is thought to reflect memory formation in the hippocampus (Walsh 2001). Furthermore, oligomeric Arctic A13 peptides display much more profound inhibitory effect than wtA(3 on LTP in the brain, likely due to their strong propensity to form A13 protofibrils (Klyubin 2003).
There are also other soluble oligomeric forms described in the literature that are distinctly different from protofibrils. One such oligomeric form is ADDL
(Arnyloid Derived Diffusible Ligand) (Lambert 1998). AFM analysis of ADDL revealed predominantly small globular species of 4.7-6.2 nm along the z-axis with molecular weights of 17-42 kDa. (Stine 1996). Another form is called ASPD
(Amyloidspheroids).
ASPD are spherical oligomers of A131-40. Toxicity studies showed that spherical ASPD >10 nm were more toxic than lower molecular forms (Hoshi 2003). The A13 fibril as the main neurotoxic species is inconsistent with the poor correlation between neuritic plaque density and AD dementia score and also with the modest signs of neurodegeneration in current APP transgenic mice. Soluble neurotoxic intermediate species and their appropriate subcellular site of formation and distribution could be the missing link that will better explain the amyloid hypothesis. This idea has gained support from recent discovery of the Arctic (E693) APP mutation, which causes early-onset AD (US 2002/0162129 Al; Nilsberth et al., 2001). The mutation is located inside the A13 peptide sequence. Mutation carriers will thereby generate variants of A13 peptides e.g. Arctic A1340 and Arctic A1342. Both Arctic A1340 and Arctic A1342 will much more easily assemble into higher molecular structures (protofibrils) that are soluble and non-fibrillar. Thus the pathogenic mechanism of the Arctic mutation suggests that the soluble higher molecular protofibrils are causing AD.
2.1 Diagnosis of Alzheimer's disease 2.1.1 Clinical diagnosis The clinical diagnosis of Alzheimer's disease (AD) is difficult to make, especially in early stages of the disease. Today, the diagnosis is based on a typical medical history combined with the exclusion of other causes of dementia. Clinical centres
There are also other soluble oligomeric forms described in the literature that are distinctly different from protofibrils. One such oligomeric form is ADDL
(Arnyloid Derived Diffusible Ligand) (Lambert 1998). AFM analysis of ADDL revealed predominantly small globular species of 4.7-6.2 nm along the z-axis with molecular weights of 17-42 kDa. (Stine 1996). Another form is called ASPD
(Amyloidspheroids).
ASPD are spherical oligomers of A131-40. Toxicity studies showed that spherical ASPD >10 nm were more toxic than lower molecular forms (Hoshi 2003). The A13 fibril as the main neurotoxic species is inconsistent with the poor correlation between neuritic plaque density and AD dementia score and also with the modest signs of neurodegeneration in current APP transgenic mice. Soluble neurotoxic intermediate species and their appropriate subcellular site of formation and distribution could be the missing link that will better explain the amyloid hypothesis. This idea has gained support from recent discovery of the Arctic (E693) APP mutation, which causes early-onset AD (US 2002/0162129 Al; Nilsberth et al., 2001). The mutation is located inside the A13 peptide sequence. Mutation carriers will thereby generate variants of A13 peptides e.g. Arctic A1340 and Arctic A1342. Both Arctic A1340 and Arctic A1342 will much more easily assemble into higher molecular structures (protofibrils) that are soluble and non-fibrillar. Thus the pathogenic mechanism of the Arctic mutation suggests that the soluble higher molecular protofibrils are causing AD.
2.1 Diagnosis of Alzheimer's disease 2.1.1 Clinical diagnosis The clinical diagnosis of Alzheimer's disease (AD) is difficult to make, especially in early stages of the disease. Today, the diagnosis is based on a typical medical history combined with the exclusion of other causes of dementia. Clinical centres
4 with high specialization can have a diagnostic accuracy of 85-90% compared with the neuropathological diagnosis. In the early stages of the disease the clinical picture is vague and definite diagnostic markers have not yet been identified (McKhann 1984). The development of biochemical diagnostic markers is important for a number of reasons: to support the clinical diagnosis, to allow clinicians to give adequate information to patients and their relatives, to initiate pharmacological treatment and care-giving, and in various aspects of clinical research.
2.1.2 Amyloid 3-peptide Pathogenic mutations in the APP and presenilin (PS) genes have been discovered in families with early-onset AD inherited as a dominant trait (Hardy 1992). The effects of some of these mutations are now fairly well understood. The Swedish AD
mutation (Mullan 1992; Axelman 1994; Lannfelt 1994) has revealed one pathogenic mechanism for the development of AD. When a cDNA construct with this mutation was transfected into human cell-lines it gave rise to approximately six times higher release of soluble AP (Citron 1992, Cai 1993). Furthermore, fibroblasts from individuals with the Swedish mutation secreted three times more Al3 into the media compared to fibroblasts from non-carriers (Johnston 1994). Overproduction of Ap therefore seemed to be an important factor in the disease pathogenesis in this Swedish family. Thus, it was expected that AP levels measured in cerebrospinal fluid (CSF) from family members would differentiate carriers from non-carriers of the mutation. However, no difference was found in levels of total AP between the groups (14.5 3.3 ng/ml versus 14.9 2.3 ng/ml) (Lannfelt 1995). One explanation for this result may be that AP is cleared from CSF by aggregating to amyloid in the brain. However, there was a strong correlation between duration of dementia and decreasing A13 levels. These measurements were done with antibodies recognizing soluble monomeric A[3. With protofibril specific monoclonal antibodies more accurate measurements of the toxic species will be possible.
2.1.3 At in plasma AB is found in a soluble form in plasma and other tissues (Seubert 1992), and not as previously presumed, only in the brains of AD cases. AP plasma levels in members of the Swedish mutation family revealed that both A1340 and A1342 were 3 times increased in mutation-carriers (Scheuner 1996). The proportion of A[342 of total A13 was approximately 10% in both groups, which is in agreement with
2.1.2 Amyloid 3-peptide Pathogenic mutations in the APP and presenilin (PS) genes have been discovered in families with early-onset AD inherited as a dominant trait (Hardy 1992). The effects of some of these mutations are now fairly well understood. The Swedish AD
mutation (Mullan 1992; Axelman 1994; Lannfelt 1994) has revealed one pathogenic mechanism for the development of AD. When a cDNA construct with this mutation was transfected into human cell-lines it gave rise to approximately six times higher release of soluble AP (Citron 1992, Cai 1993). Furthermore, fibroblasts from individuals with the Swedish mutation secreted three times more Al3 into the media compared to fibroblasts from non-carriers (Johnston 1994). Overproduction of Ap therefore seemed to be an important factor in the disease pathogenesis in this Swedish family. Thus, it was expected that AP levels measured in cerebrospinal fluid (CSF) from family members would differentiate carriers from non-carriers of the mutation. However, no difference was found in levels of total AP between the groups (14.5 3.3 ng/ml versus 14.9 2.3 ng/ml) (Lannfelt 1995). One explanation for this result may be that AP is cleared from CSF by aggregating to amyloid in the brain. However, there was a strong correlation between duration of dementia and decreasing A13 levels. These measurements were done with antibodies recognizing soluble monomeric A[3. With protofibril specific monoclonal antibodies more accurate measurements of the toxic species will be possible.
2.1.3 At in plasma AB is found in a soluble form in plasma and other tissues (Seubert 1992), and not as previously presumed, only in the brains of AD cases. AP plasma levels in members of the Swedish mutation family revealed that both A1340 and A1342 were 3 times increased in mutation-carriers (Scheuner 1996). The proportion of A[342 of total A13 was approximately 10% in both groups, which is in agreement with
5 PCT/SE2005/000993 experiments performed in cell cultures with the Swedish mutation. Mutation-carriers below the age of expected onset of the disease had the same levels of AB as already affected cases. This indicates that APP mismetabolism may play an important role early in the pathogenesis of the disease.
2.1.4 Af342 in CSF in Alzheimer's disease ELISAs specifically measuring A1340 and A1342 in CSF in AD cases have given different results. Some researchers (Pirttild 1994; Motter 1995) have found decreased AB42 in AD, while one group have found elevated levels in cases early in the disease progression. The most demented cases in one study had all very low levels of A142.
In conclusion, AfS42 is most likely increased early in the disease process and levels of A1342 and A1340 decreased during progression of the disease. The development of accurate biochemical markers of early AD is important especially when efficient pharmacological treatments will be available in the future. Pharmacological therapy should most likely be initiated at an early stage of disease, before severe brain damage has occurred. A therapy making it possible to prevent the progression of the disease to its later stages would therefore be much desired.
2.2 Prevention and treatment of Alzheimer's disease Antibodies that are specific towards different conformations of AP, such as AP
fibrils (0 Wuallain 2002), micellar Ap (Kayed 2003), ADDL (M93, M94) (Lambert 2001) have also been described.
Several pre-clinical studies in transgenic animal models have shown decreased plaque burden and improvements in memory function after active or passive immunization with antibodies raised against fibrils (Shenk 1999, Janus 2000, Morgan 2000, Weiner 2000, Sigurdsen 2001). Since fibrils are present in pathological deposits occurring late in the Alzheimer disease process, the Shenk antibodies may only be used to slow the progression of Alzheimer's disease when it has already reached its later stages.
Recently, a phase II clinical trial in Alzheimer patients with mild to moderate dementia was performed by ELAN Pharmaceuticals with their vaccine AN 1792, which is an aggregated preparation of human wtAp42. The study had to be stopped
2.1.4 Af342 in CSF in Alzheimer's disease ELISAs specifically measuring A1340 and A1342 in CSF in AD cases have given different results. Some researchers (Pirttild 1994; Motter 1995) have found decreased AB42 in AD, while one group have found elevated levels in cases early in the disease progression. The most demented cases in one study had all very low levels of A142.
In conclusion, AfS42 is most likely increased early in the disease process and levels of A1342 and A1340 decreased during progression of the disease. The development of accurate biochemical markers of early AD is important especially when efficient pharmacological treatments will be available in the future. Pharmacological therapy should most likely be initiated at an early stage of disease, before severe brain damage has occurred. A therapy making it possible to prevent the progression of the disease to its later stages would therefore be much desired.
2.2 Prevention and treatment of Alzheimer's disease Antibodies that are specific towards different conformations of AP, such as AP
fibrils (0 Wuallain 2002), micellar Ap (Kayed 2003), ADDL (M93, M94) (Lambert 2001) have also been described.
Several pre-clinical studies in transgenic animal models have shown decreased plaque burden and improvements in memory function after active or passive immunization with antibodies raised against fibrils (Shenk 1999, Janus 2000, Morgan 2000, Weiner 2000, Sigurdsen 2001). Since fibrils are present in pathological deposits occurring late in the Alzheimer disease process, the Shenk antibodies may only be used to slow the progression of Alzheimer's disease when it has already reached its later stages.
Recently, a phase II clinical trial in Alzheimer patients with mild to moderate dementia was performed by ELAN Pharmaceuticals with their vaccine AN 1792, which is an aggregated preparation of human wtAp42. The study had to be stopped
6 due to side effects in 5% of the patients. The side effect was considered to be due to T-lymphocyte-induced meningioencephalitis (Nicholl 2003). The drug targets of the ELAN vaccine were insoluble fibrils found in plaques inside the brain and deposits on the brain blood vessel walls (Congophilic Amyloid Angiopathy, CAA), which are common features of Alzheimer's disease. Thus, an immune response towards insoluble fibrils could be responsible for the invasive inflammation in the brain blood vessel walls leading to meningioencephalitis.
W002/203911 disclose the discovery of the Arctic mutation in a Swedish family leading to early onset of Alzheimer's disease (55.6 years). The Arctic mutation (Glu>Gly), which is located at position 22 in the beta amyloid peptide (AB), in combination with various experiments led to the insight that the AB peptide was much more prone to oligomerize and form protofibrils compared to wild type A4340.
The discovery indicated for the first time that the protofibril is a central component in the disease process, and that AD could be treated by reducing the amount of protofibrils in the brain. This unique property of the Arctic mutation could then be used to generate protofibrils. W002/203911 then suggested that said protofibrils could be used to immunize a mouse or other animal, in order to generate antibodies, after which any protofibril-specific monoclonal antibody could identified be screening. Said antibodies should then be specific towards an AP peptide of SEQ
ID No 1 (page 7, third paragraph), i.e. a peptide carrying the Arctic mutation and having a protofibril conformation.
Thus, in view of the prior art techniques for preventing and treating Alzheimer's disease, there is a need for a technique that enables earlier detection of markers of Alzheimer's disease. If said markers could be prevented without causing negative side-effects, this would be a means to prevent and treat Alzheimer's disease at an early stage. Any treatment of Alzheimer's disease that would reduce the amount of protofibrils in the brain of AD patients, would be of significant therapeutic value.
3. DESCRIPTION OF THE INVENTION
Protofibrils occur early in Alzheimer's disease, when little brain damage has occurred. An antibody treatment that reduce protofibril levels in the brain will save the brain from neuronal destruction and hence be more advantageous for Alzheimer
W002/203911 disclose the discovery of the Arctic mutation in a Swedish family leading to early onset of Alzheimer's disease (55.6 years). The Arctic mutation (Glu>Gly), which is located at position 22 in the beta amyloid peptide (AB), in combination with various experiments led to the insight that the AB peptide was much more prone to oligomerize and form protofibrils compared to wild type A4340.
The discovery indicated for the first time that the protofibril is a central component in the disease process, and that AD could be treated by reducing the amount of protofibrils in the brain. This unique property of the Arctic mutation could then be used to generate protofibrils. W002/203911 then suggested that said protofibrils could be used to immunize a mouse or other animal, in order to generate antibodies, after which any protofibril-specific monoclonal antibody could identified be screening. Said antibodies should then be specific towards an AP peptide of SEQ
ID No 1 (page 7, third paragraph), i.e. a peptide carrying the Arctic mutation and having a protofibril conformation.
Thus, in view of the prior art techniques for preventing and treating Alzheimer's disease, there is a need for a technique that enables earlier detection of markers of Alzheimer's disease. If said markers could be prevented without causing negative side-effects, this would be a means to prevent and treat Alzheimer's disease at an early stage. Any treatment of Alzheimer's disease that would reduce the amount of protofibrils in the brain of AD patients, would be of significant therapeutic value.
3. DESCRIPTION OF THE INVENTION
Protofibrils occur early in Alzheimer's disease, when little brain damage has occurred. An antibody treatment that reduce protofibril levels in the brain will save the brain from neuronal destruction and hence be more advantageous for Alzheimer
7 patients. The present invention describes the development of such therapeutic protofibril specific antibodies.
According to one aspect, the present invention relates to antibodies that have the property to bind both wild type A1342/40 and A[342/ 40arc protofibrils (conformation-specific antibodies) and which are suitable for development into pharmaceuticals for Alzheimer's disease, targeting wild type A42/ 4O
protofibrils.
Current ideas in the field of Alzheimer's disease research is that Ap fibrils are the main cause of the disease. Hence, the approach of the present invention contradicts the general opinion within the field.
According to another aspect, the present invention also relates to a composition comprising said antibody and optionally a carrier or excipient.
To immunise and screen for conformation-specific anti-protofibril antibodies, it is necessary to produce pure A1342arc and Af342 protofibrils (>95% degree of purity).
In order to obtain said pure protofibril preparation, it is also necessary to be able to stabilise the protofibrils, such that they stay protofibrils and do not separate into monomers or aggregate into fibrils. It is also necessary to find a solvent that made it possible to separate the protofibrils by column chromatography. Another necessity is the ability to test said purity before immunisation. The above-mentioned abilities are essential, since the degree of purity of the antigen (protofibrils) decide the possibility to produce conformation-specific anti-protofibril antibodies, which in turn decide the possibility to screen for antibodies with useful specificity.
Should the preparation for example contain 50% A13 monomer and 50% Ai3 protofibril, it is only possible to claim that the antibody binding said preparation may bind both forms or only one. All of said necessary features are provided by the present invention.
The above-mentioned features were not possible when W002/ 203911 was filed.
The HPLC analysis method disclosed it the present application or any other analysis method had not been developed, wherefore it was not possible to determine whether the A1342arc peptide actually formed protofibrils, probably due to the lack of binding to protofibrils. It was only a hypothesis at the time. The major reasons why W002/ 203911 could not analyse and purify protofibril preparation to a degree of
According to one aspect, the present invention relates to antibodies that have the property to bind both wild type A1342/40 and A[342/ 40arc protofibrils (conformation-specific antibodies) and which are suitable for development into pharmaceuticals for Alzheimer's disease, targeting wild type A42/ 4O
protofibrils.
Current ideas in the field of Alzheimer's disease research is that Ap fibrils are the main cause of the disease. Hence, the approach of the present invention contradicts the general opinion within the field.
According to another aspect, the present invention also relates to a composition comprising said antibody and optionally a carrier or excipient.
To immunise and screen for conformation-specific anti-protofibril antibodies, it is necessary to produce pure A1342arc and Af342 protofibrils (>95% degree of purity).
In order to obtain said pure protofibril preparation, it is also necessary to be able to stabilise the protofibrils, such that they stay protofibrils and do not separate into monomers or aggregate into fibrils. It is also necessary to find a solvent that made it possible to separate the protofibrils by column chromatography. Another necessity is the ability to test said purity before immunisation. The above-mentioned abilities are essential, since the degree of purity of the antigen (protofibrils) decide the possibility to produce conformation-specific anti-protofibril antibodies, which in turn decide the possibility to screen for antibodies with useful specificity.
Should the preparation for example contain 50% A13 monomer and 50% Ai3 protofibril, it is only possible to claim that the antibody binding said preparation may bind both forms or only one. All of said necessary features are provided by the present invention.
The above-mentioned features were not possible when W002/ 203911 was filed.
The HPLC analysis method disclosed it the present application or any other analysis method had not been developed, wherefore it was not possible to determine whether the A1342arc peptide actually formed protofibrils, probably due to the lack of binding to protofibrils. It was only a hypothesis at the time. The major reasons why W002/ 203911 could not analyse and purify protofibril preparation to a degree of
8 purity of >95%. Also, to the fact that they did not know how to stabilise protofibrils.
In that connection, it should also be mentioned that protofibrils are very difficult to handle in comparison with for example A1340 peptides. A1342, but in particular the Af642Arc peptide, is extremely difficult to handle, since they stick to test tubes and columns and aggregate into fibrils. The latter problems has been solved by the present invention by the provision of methods to stabilise the protofibrils involving low temperatures and selected solvents. W002/203911 also had no means for testing the purity of the protofibrils before immunisation. This is possible with the present invention by the provision of a new HPLC (size exclusion) method. In addition to this, W002/203911 did not provide any means to check the protofibril specificity of the screened antibodies. The present invention makes this possible by the provision of a new Elisa method. W002/203911 could only produce impure and transient A1340arc protofibrils, not useful for monoclonal development of protofibril specific antibodies (W002/203911 only describes analysis of AZ40 and AMOArc peptides, see Example 3).
The antibodies according to the present invention are particularly suitable for treating Alzheimer's disease since they will: i) target and eliminate the most toxic AB
form (protofibril), ii) provide an opportunity to treat the disease early since protofibrils develops early in the disease process, iii) avoid side-effects since the will not significantly cross-react with AS fibrils present in the blood vessel wall of the brain (CAA= Congophilic Amyloidogenic Angiopathy).
The antibodies according to the present invention may be human or humanised, monoclonal or polyclonal. The present invention also relates to biologically active fragments of said antibodies, with the proviso that they still have the claimed properties.
The A13 protofibril specific antibodies according to the present invention can also be used to quantitate wild type A1342/40 protofibrils in biological fluids, thus the antibodies will be suitable for clinical diagnosis at an early stage of the disease and suitable as a biomarker to monitor efficacy in clinical studies.
In that connection, it should also be mentioned that protofibrils are very difficult to handle in comparison with for example A1340 peptides. A1342, but in particular the Af642Arc peptide, is extremely difficult to handle, since they stick to test tubes and columns and aggregate into fibrils. The latter problems has been solved by the present invention by the provision of methods to stabilise the protofibrils involving low temperatures and selected solvents. W002/203911 also had no means for testing the purity of the protofibrils before immunisation. This is possible with the present invention by the provision of a new HPLC (size exclusion) method. In addition to this, W002/203911 did not provide any means to check the protofibril specificity of the screened antibodies. The present invention makes this possible by the provision of a new Elisa method. W002/203911 could only produce impure and transient A1340arc protofibrils, not useful for monoclonal development of protofibril specific antibodies (W002/203911 only describes analysis of AZ40 and AMOArc peptides, see Example 3).
The antibodies according to the present invention are particularly suitable for treating Alzheimer's disease since they will: i) target and eliminate the most toxic AB
form (protofibril), ii) provide an opportunity to treat the disease early since protofibrils develops early in the disease process, iii) avoid side-effects since the will not significantly cross-react with AS fibrils present in the blood vessel wall of the brain (CAA= Congophilic Amyloidogenic Angiopathy).
The antibodies according to the present invention may be human or humanised, monoclonal or polyclonal. The present invention also relates to biologically active fragments of said antibodies, with the proviso that they still have the claimed properties.
The A13 protofibril specific antibodies according to the present invention can also be used to quantitate wild type A1342/40 protofibrils in biological fluids, thus the antibodies will be suitable for clinical diagnosis at an early stage of the disease and suitable as a biomarker to monitor efficacy in clinical studies.
9 Furthermore, the invention describes procedures to generate wild type A1342 arid A1342arc protofibrils as antigens for immunization and for reagents to screen for antibodies that binds A1342arc and wild type A842 protofibrils.
Antigen (protofibril) purity is very important to determine in antibody screening experiments, since it affects antibody specificity determinations by ELISA.
To asses the purity of antigen (A(342arc and wild type A1342 protofibrils) preparation, a size exclusion HPLC method has been developed. The HPLC method invented uses a detergent, with low optical interference in chromatography. The detergent has the advantage that it eliminates interactions of A.1342arc and wild type Ai342 protofibrils with the column matrix, preventing loss of material and material from adhering to the column, and erroneous estimations of protofibril purity. Furthermore, the detergent is compatible with Al) protofibrils and does not solubffize them into Al) monomers or alter their biological profile. Polysorbate (Tweerif has been found to be TM
a suitable detergent, in particular Polysorbate-80 (Tween-80). Other detergents with similar properties are also useful.
The antibody according to the present cross-reacts less than 50% with AB
fibrils.
Said antibody can detect both wild type A.I3 protofibrils and Arctic AL S
protofibrils in an ELISA in a concentration range of 1000-10 ng/ml (see Example 5 and Figures 4A-C). In an optimised ELISA or by other detection systems with higher sensitivity, for example proximity ligation, said detection level could probably be brought down to a detection level of 1-0.1 ng/ml.
The present invention provides a method to raise antibodies that are specific to amyloid (3 (Al)) protofibrils (high molecular weight soluble non-fibrillar Al) oligomers).
The antibodies are raised against Al) in its protofibril conformation. These antibodies will be administered to AD patients to reduce protofibril levels in the brain, which will be of significant therapeutic value.
The lowering of protofibril levels might occur through the elimination of the antigen when bound to an antibody, through microglia-mediated phagocytosis. This is a well documented biological process, which occurs through the binding of the antibody's constant region (Fc) to an Fc receptor on microg,lial cells.
Binding induces phagocytosis (internalisation and destruction) of the antibody and its bound antigen (protofibril) leading to reduced levels of protofibrils in the brain.
Other non-Fc receptor mediated processes might also occur to eliminate the antigen (protofibril).
Another aspect of the invention pertains to a method to synthesize Ap protofibrils which are to be used as antigen for immunization. The synthesis can be made from wild type Af3 (wtAf3) or alternatively, from non-wild type, mutated or modified forms of All In a preferred embodiment of the invention, but not limited to said embodiment, the synthesis is initiated by dissolving wtAf31-42 in a dissociating agent, for example NaOH, to achieve a homogenous A13 solution, of about 50-500 uM in peptide concentration, but not limited to this concentration.
Alternative agents with dissociating capacity are for example dimethylsulfoxide, DMSO;
hexafluoroisopropanol, HFIP; trifluoroacetic acid, TFA. Wild type protofibrils can also be made from wtA13 peptides of different lengths i.e. wtAf31-39, wtA131-40, wtA131-43 or N-terminal truncated forms of these peptides. The truncation can be 1-
Antigen (protofibril) purity is very important to determine in antibody screening experiments, since it affects antibody specificity determinations by ELISA.
To asses the purity of antigen (A(342arc and wild type A1342 protofibrils) preparation, a size exclusion HPLC method has been developed. The HPLC method invented uses a detergent, with low optical interference in chromatography. The detergent has the advantage that it eliminates interactions of A.1342arc and wild type Ai342 protofibrils with the column matrix, preventing loss of material and material from adhering to the column, and erroneous estimations of protofibril purity. Furthermore, the detergent is compatible with Al) protofibrils and does not solubffize them into Al) monomers or alter their biological profile. Polysorbate (Tweerif has been found to be TM
a suitable detergent, in particular Polysorbate-80 (Tween-80). Other detergents with similar properties are also useful.
The antibody according to the present cross-reacts less than 50% with AB
fibrils.
Said antibody can detect both wild type A.I3 protofibrils and Arctic AL S
protofibrils in an ELISA in a concentration range of 1000-10 ng/ml (see Example 5 and Figures 4A-C). In an optimised ELISA or by other detection systems with higher sensitivity, for example proximity ligation, said detection level could probably be brought down to a detection level of 1-0.1 ng/ml.
The present invention provides a method to raise antibodies that are specific to amyloid (3 (Al)) protofibrils (high molecular weight soluble non-fibrillar Al) oligomers).
The antibodies are raised against Al) in its protofibril conformation. These antibodies will be administered to AD patients to reduce protofibril levels in the brain, which will be of significant therapeutic value.
The lowering of protofibril levels might occur through the elimination of the antigen when bound to an antibody, through microglia-mediated phagocytosis. This is a well documented biological process, which occurs through the binding of the antibody's constant region (Fc) to an Fc receptor on microg,lial cells.
Binding induces phagocytosis (internalisation and destruction) of the antibody and its bound antigen (protofibril) leading to reduced levels of protofibrils in the brain.
Other non-Fc receptor mediated processes might also occur to eliminate the antigen (protofibril).
Another aspect of the invention pertains to a method to synthesize Ap protofibrils which are to be used as antigen for immunization. The synthesis can be made from wild type Af3 (wtAf3) or alternatively, from non-wild type, mutated or modified forms of All In a preferred embodiment of the invention, but not limited to said embodiment, the synthesis is initiated by dissolving wtAf31-42 in a dissociating agent, for example NaOH, to achieve a homogenous A13 solution, of about 50-500 uM in peptide concentration, but not limited to this concentration.
Alternative agents with dissociating capacity are for example dimethylsulfoxide, DMSO;
hexafluoroisopropanol, HFIP; trifluoroacetic acid, TFA. Wild type protofibrils can also be made from wtA13 peptides of different lengths i.e. wtAf31-39, wtA131-40, wtA131-43 or N-terminal truncated forms of these peptides. The truncation can be 1-
10 amino acids, giving wtA13 forms such as: wtAf32-42, wtA133-42, wtA134-42, wtAf35-42 and so on. The dissolved wtAf31-42 peptide is subsequently neutralized by PBS
or similar physiological buffer and incubated at higher temperature, preferably 370 C, for a period of time sufficient for protofibril-formation to occur, for example over night. This will yield wild type Af3 protofibrils. The invention also provide a molecular size (molecular weight) determination method to asses protofibril formation and purity, preferably, but not limited to, a size-exclusion chromatographic method (SEC).
The method of synthesizing pure wild type (wtAI342) protofibril antigen, comprises the steps of dissolving an wtA1342 by using a dissociating agent, such as NaOH
(pH>10), dimethylsulfoxide, DMSO; hexafluoroisopropanol, HFIP; trifluoroacetic acid and TFA, to achieve a monodisperse solution, neutralizing the solution by PBS
(pH 7-8) or similar biocompatible buffers, to achieve a physiological solution, incubating the neutralized wtA(342 peptide solution at an elevated protein concentration between 1-1000 uM, preferably 440 uM, for 6 hours or longer at 40 0C, preferably 37 0C, to form Af342wt protofibrils, diluting the protofibrils to approximately 1-500uM, preferably 50uM centrifuging at sufficient speed and time to sediment wtA1342 fibrils, which normally takes 5 minutes at 17.000 x g at +4 C,
or similar physiological buffer and incubated at higher temperature, preferably 370 C, for a period of time sufficient for protofibril-formation to occur, for example over night. This will yield wild type Af3 protofibrils. The invention also provide a molecular size (molecular weight) determination method to asses protofibril formation and purity, preferably, but not limited to, a size-exclusion chromatographic method (SEC).
The method of synthesizing pure wild type (wtAI342) protofibril antigen, comprises the steps of dissolving an wtA1342 by using a dissociating agent, such as NaOH
(pH>10), dimethylsulfoxide, DMSO; hexafluoroisopropanol, HFIP; trifluoroacetic acid and TFA, to achieve a monodisperse solution, neutralizing the solution by PBS
(pH 7-8) or similar biocompatible buffers, to achieve a physiological solution, incubating the neutralized wtA(342 peptide solution at an elevated protein concentration between 1-1000 uM, preferably 440 uM, for 6 hours or longer at 40 0C, preferably 37 0C, to form Af342wt protofibrils, diluting the protofibrils to approximately 1-500uM, preferably 50uM centrifuging at sufficient speed and time to sediment wtA1342 fibrils, which normally takes 5 minutes at 17.000 x g at +4 C,
11 assessing the purity of the protofibril preparation by HPLC to control that the purity is >95%, using for example size exclusion HPLC, using a physiological buffer such as PBS at neutral pH as running buffer, including a detergent, such as Polysorbate (Tween), or similar detergent, to avoid sticking of the protofibrils to the column matrix and dissociation.
Another aspect of the invention pertains to the synthesis of non-wild type A13 protofibrils using A131-42, A31-41, A[31-40 or Ar31-39 or N-terminal truncated forms (1-10 truncations) with either the Arctic (G22E) mutation (US 09/899,815), the Dutch mutation (E22Q), the Flemish (A21G)mutation, the Italian (E22K) mutation, the Iowa (D23N) mutation, and combinations thereof. In a preferred embodiment of the invention A1342arc peptide (i.e., comprising the arctic mutation) is used.
The method to make A1342arc protofibrils is similar to that for wtA1342 protofibrils except that A[342arc protofibrils are not incubated at 37 C over night since they are spontaneously formed after the neutralization step.
The method of synthesizing pure A1342arc protofibril antigen comprises the steps of dissolving an A1342arc peptide by using a dissociating agent, such as NaOH
(pH>10), dimethylsulkodde, DMSO; hexafluoroisopropanol, HFIP; trifluoroacetic acid and TFA to achieve a monodisperse solution, neutralizing the solution by PBS
(pH 7-8) or similar biocompatible buffers, to achieve a physiological solution, stabilizing the spontaneously formed protofibrils by keeping them at below 20 C, preferably at 0-5 C, centrifuging the protofibrils, at the same temperature as in the stabilising step, at a sufficient speed and time to sediment Af342arc fibrils, which normally takes 5 minutes at 17.000 x g at +4 C, assessing the purity of the protofibril preparation by HPLC to control that the purity is >95%, using for example size exclusion HPLC, using a physiological buffer such as PBS at neutral pH as running buffer, including a detergent, such as Polysorbate (Tween), or similar detergent, to avoid sticking of the protofibrils to the column matrix and dissociation.
Another aspect of the invention pertains to the development of antibodies that cross-react with wild type A1342 protofibrils after immunization with A1342arc protofibrils.
Another aspect of the invention pertains to the synthesis of non-wild type A13 protofibrils using A131-42, A31-41, A[31-40 or Ar31-39 or N-terminal truncated forms (1-10 truncations) with either the Arctic (G22E) mutation (US 09/899,815), the Dutch mutation (E22Q), the Flemish (A21G)mutation, the Italian (E22K) mutation, the Iowa (D23N) mutation, and combinations thereof. In a preferred embodiment of the invention A1342arc peptide (i.e., comprising the arctic mutation) is used.
The method to make A1342arc protofibrils is similar to that for wtA1342 protofibrils except that A[342arc protofibrils are not incubated at 37 C over night since they are spontaneously formed after the neutralization step.
The method of synthesizing pure A1342arc protofibril antigen comprises the steps of dissolving an A1342arc peptide by using a dissociating agent, such as NaOH
(pH>10), dimethylsulkodde, DMSO; hexafluoroisopropanol, HFIP; trifluoroacetic acid and TFA to achieve a monodisperse solution, neutralizing the solution by PBS
(pH 7-8) or similar biocompatible buffers, to achieve a physiological solution, stabilizing the spontaneously formed protofibrils by keeping them at below 20 C, preferably at 0-5 C, centrifuging the protofibrils, at the same temperature as in the stabilising step, at a sufficient speed and time to sediment Af342arc fibrils, which normally takes 5 minutes at 17.000 x g at +4 C, assessing the purity of the protofibril preparation by HPLC to control that the purity is >95%, using for example size exclusion HPLC, using a physiological buffer such as PBS at neutral pH as running buffer, including a detergent, such as Polysorbate (Tween), or similar detergent, to avoid sticking of the protofibrils to the column matrix and dissociation.
Another aspect of the invention pertains to the development of antibodies that cross-react with wild type A1342 protofibrils after immunization with A1342arc protofibrils.
12 Another aspect of the invention pertains to a method to stabilize A(3 protofibril and where stabilization can be assessed by size-exclusion chromatography (SEC). Ap protofibrils elutes after 12-13 minutes in a uniform peak on a Superdex 7glofr similar size-exclusion column. Conformation stability can also be assessed by staining with Congo Red and (electron microscopy), where protofibrils attain a curve-linear structure of 6-10 rim in diameter and <200 run in length. Lowered temperature has a significant effect on Ap protofibril conformational stability.
Samples should preferably be kept below 20 C, preferably below 5 C, and most between 0 C and 5 C. Furthermore, agents that decrease the polarity or surface tension or increase viscosity have stabilizing effects on AP protofibril conformation.
For example, 10-50% glycerol or 0.6-5% Polysorbate (Tween), have stabilizing effects on Ap protofibrils. These agents and treatments can be added to the Ap protofibril preparation preferably after the neutralization step in the method to synthesize Ap protofibrils described above. Addition of these agents before this step is also possible. Increased stability of protofibrils is advantageous when developing monoclonal antibodies and when Ap protofibrils are used as reagents in immunoassays, such as ELISA, radio-immunoassay (RIA), Western blotting or dot blotting.
The method of stabilizing the Af3 protofibrils includes mixing them with an agent that decreases the solvent polarity or one that lowers the surface tension, such as glycerol or Polysorbate (Tween), or a combination of said agents. The stabilisation can also be achieved by keeping the protofibrils at a temperature below 200C, preferably 0-5 C. Said methods can also be combined.
The invention further pertains to the use of anti-AP protofibril specific antibodies for determinations of Ap protofibrils in human and animal tissues, for example, cerebrospinal fluid, blood, serum, urine and brain tissue, but is not limited to these tissues, providing for a possible diagnostic method for Alzheimer's disease.
Suitable methods for assaying AP protofibrils in these tissues as well as in cell cultures using an anti-AP protofibril antibody are immunoassays such as ELISA, RIA, Western blotting dot blotting or proximity ligation. The method would be suitable to
Samples should preferably be kept below 20 C, preferably below 5 C, and most between 0 C and 5 C. Furthermore, agents that decrease the polarity or surface tension or increase viscosity have stabilizing effects on AP protofibril conformation.
For example, 10-50% glycerol or 0.6-5% Polysorbate (Tween), have stabilizing effects on Ap protofibrils. These agents and treatments can be added to the Ap protofibril preparation preferably after the neutralization step in the method to synthesize Ap protofibrils described above. Addition of these agents before this step is also possible. Increased stability of protofibrils is advantageous when developing monoclonal antibodies and when Ap protofibrils are used as reagents in immunoassays, such as ELISA, radio-immunoassay (RIA), Western blotting or dot blotting.
The method of stabilizing the Af3 protofibrils includes mixing them with an agent that decreases the solvent polarity or one that lowers the surface tension, such as glycerol or Polysorbate (Tween), or a combination of said agents. The stabilisation can also be achieved by keeping the protofibrils at a temperature below 200C, preferably 0-5 C. Said methods can also be combined.
The invention further pertains to the use of anti-AP protofibril specific antibodies for determinations of Ap protofibrils in human and animal tissues, for example, cerebrospinal fluid, blood, serum, urine and brain tissue, but is not limited to these tissues, providing for a possible diagnostic method for Alzheimer's disease.
Suitable methods for assaying AP protofibrils in these tissues as well as in cell cultures using an anti-AP protofibril antibody are immunoassays such as ELISA, RIA, Western blotting dot blotting or proximity ligation. The method would be suitable to
13 follow treatment efficacy (protofibril reduction) in clinical trials and suitable as a diagnostic test for Alzheimer's disease or Down's syndrome.
The method of diagnosing or monitoring Alzheimer's disease (AD) or Down's syndrome comprises the steps of labelling the antibody according to the present invention with an agent that can generate a measurable signal., administering said antibody according to a subject having or suspected of having AD or Down's syndrome, measuring the amount of protofibrils bound to the antibody by measuring the signal generated by the agent.
The invention further pertains to the use of an anti-AP protofibril antibody in imaging for detection, localization and quantitation of AP protofibrils in human and animal tissues. The anti-Ait protofibril antibody could be label with a radioactive ligand such as 1131, C14, H3 or Gallium68, but it is not limited to these radioisotopes, for detection purposes. In addition to labelling with radioactive markers, DNA, fluorescent molecules, enzymes which converts a substrate such that its absorbance can be measured, could also be used. The method will be suitable as a diagnostic tool for Alzheimer's disease or Down's syndrome, Lew-ybody dementia, vascular dementia, and other neurodegenerative disorders.
A further aspect of the invention pertains to the use of an anti-Ap protofibril antibody for the prevention or treatment of Alzheimer's disease. Pre-clinical studies in transgenic animal models have demonstrated effects on plaque burden (Bard 2000), reversal of memory deficits (Dodard 2002) and drainage of Af3 from CNS
after anti-Af3 antibody treatment. However, the antibodies used in these studies have not been specific to A13 protofibrils. Administration of an anti-Af3 protofibril antibody, with no or little cross-reactivity towards A13 monomers and fibrils would be particular suitable for treatment and prevention of Alzheimer's disease.
Firstly, it would not bind significantly to fibrillar forms of Af3 and avoid interaction with fibrillar deposits which are prevalent in blood vessel walls, avoiding sever immunoreactions with concomitant serious brain inflammation and encephalitis, which was encountered in the ELAN vaccination study (see at the end of the Background) with their vaccine AN-1792 (Nicoll 2004). Secondly, an anti-Af3 protofibril antibody with low A131-40 and A[31-42 monomer cross-reactivity would
The method of diagnosing or monitoring Alzheimer's disease (AD) or Down's syndrome comprises the steps of labelling the antibody according to the present invention with an agent that can generate a measurable signal., administering said antibody according to a subject having or suspected of having AD or Down's syndrome, measuring the amount of protofibrils bound to the antibody by measuring the signal generated by the agent.
The invention further pertains to the use of an anti-AP protofibril antibody in imaging for detection, localization and quantitation of AP protofibrils in human and animal tissues. The anti-Ait protofibril antibody could be label with a radioactive ligand such as 1131, C14, H3 or Gallium68, but it is not limited to these radioisotopes, for detection purposes. In addition to labelling with radioactive markers, DNA, fluorescent molecules, enzymes which converts a substrate such that its absorbance can be measured, could also be used. The method will be suitable as a diagnostic tool for Alzheimer's disease or Down's syndrome, Lew-ybody dementia, vascular dementia, and other neurodegenerative disorders.
A further aspect of the invention pertains to the use of an anti-Ap protofibril antibody for the prevention or treatment of Alzheimer's disease. Pre-clinical studies in transgenic animal models have demonstrated effects on plaque burden (Bard 2000), reversal of memory deficits (Dodard 2002) and drainage of Af3 from CNS
after anti-Af3 antibody treatment. However, the antibodies used in these studies have not been specific to A13 protofibrils. Administration of an anti-Af3 protofibril antibody, with no or little cross-reactivity towards A13 monomers and fibrils would be particular suitable for treatment and prevention of Alzheimer's disease.
Firstly, it would not bind significantly to fibrillar forms of Af3 and avoid interaction with fibrillar deposits which are prevalent in blood vessel walls, avoiding sever immunoreactions with concomitant serious brain inflammation and encephalitis, which was encountered in the ELAN vaccination study (see at the end of the Background) with their vaccine AN-1792 (Nicoll 2004). Secondly, an anti-Af3 protofibril antibody with low A131-40 and A[31-42 monomer cross-reactivity would
14 not bind and interfere with their normal biological functions, thus avoiding side effects.
In said method of prevention or treatment of Alzheimer's disease or Down's a subject having or suspected of having Alzheimer's disease, Down's syndrome, Lewybody dementia, vascular dementia, and other neurodegenerative disorders, is administered the antibody or composition according to the present invention.
The invention also provides a technique whereby anti-A13protofibril antibodies can be used to identify and select for epitopes present on AP protofibrils but less on AP
monomers and Ap fibrils or other A13 conformational forms. The method is general and is applicable to other amyloids forming protofibrils such as, but not limited to, islet amyloid protein peptide (IAPP, amylin) associated with Type-2 diabetes ,prion protein (PrP), alpha-synuclein (Parkinson). Considering the central role of amyloid beta (A13) protofibrils in Alzheimer's disease, these antibodies can be used to diagnose or treat Alzheimer's disease. There is a need for a method that specifically can determine protofibrils in different human and animal tissues such as cerebral spinal fluid (CSF), plasma, blood, urine and brain tissue, but is not limited to these tissues. Such a method could be used as a diagnostic method for Alzheimer's disease but also for similar diseases that forms amyloid protofibrils including Parkinson (alpha-synuclein) (Sthilerman 2002), Type-2 diabetes (Islet amyloid polypeptide, IAPP) (W003/ 092619 A2), and Creutzfeldt-Jacob Disease and the corresponding animal disease called mad cow disease (Prion protein) (DeMarco 2004) , but is not limited to these diseases.
According to another aspect, the present invention relates to the use of anti-protofibril antibodies for in vitro or in vivo screening of substances that inhibit or modulate AP protoflbril levels and/or activity in cell cultures or animal models, being potential Alzheimer drugs. Suitable screening systems would be, but are not limited to, cell cultures (HEC or neuroblastoma cells) or for example the Thy-APPSweArc transgenic mouse model, (Nilsson L. et al. Swedish patent application 0400707-6, 2004) that expresses human Amyloid Precursor Protein (APP) with the Arctic mutation (E693G) providing increased production of A13 protofibrils.
Alzheimer drug candidates can be administered to these cell cultures or transgenic animal models and their effects on AP protofibril levels measured by an immunoassay, using an anti-AP protofibril antibody as reagent. Such method would be ideally suitable for identifying potent Alzheimer drug candidates.
Said method for in vitro or in vivo screening of substances that inhibit or modulate AP protofibril levels and/or activity in cell cultures or animal models, comprises the steps of administering potential drug candidates to a cell culture or an animal model, administering the antibody according to any the present invention, labelled with an agent that can generate a measurable signal, to said cell culture or animal model, evaluating the effect of said drug candidates by measuring the amount of protofibrils bound to the antibody by measuring the signal generated by the agent.
According to another aspect, the present invention relates to a method of detecting Ap protofibrils in vitro, comprising labelling the according to the present invention with an agent that can generate a measurable signal, contacting said antibody or the composition comprising the antibody with a biological sample suspected of containing soluble protofibrils, measuring the amount of protofibrils bound to the antibody by measuring the signal generated by the agent. Said method may be an immunoassay. The biological samples tested may be selected from plasma, CSF, brain and other tissues of animal or human origin. The labelling includes labelling with radioactive markers, DNA, fluorescent molecules, enzymes which converts a substrate such that its absorbance can be measured.
Provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that is specific for amyloid beta peptide (AP) protofibrils, and binds and A340 wild-type protofibril and A1342 and A1340 arc protofibril with low A(340 and A342 monomer cross-reactivity.
15a Also provided herein is a method of detecting amyloid beta peptide (Am protofibrils in vitro, comprising:
-labelling the antibody according to any one of claims 1-3 or in the composition according to claim 4 with an agent that can generate a measurable signal, -contacting said antibody or the composition comprising the antibody with a biological sample suspected of containing soluble protofibrils, -measuring the amount of protofibrils bound to the antibody by measuring the signal generated by the agent.
Further provided herein is a method for in vitro or in vivo screening of substances that inhibit amyloid beta peptide (A3) protofibril levels and/or activity in cell cultures or animal models genetically engineered to have high levels of amyloid beta peptide (AP ) protofibrils, comprising the steps of:
-administering potential drug candidates to a cell culture or an animal model, -administering an antibody according to any one of claims 1-3 or in the composition according to claim 4, labelled with an agent that can generate a measurable signal, to said cell culture or animal model -evaluating the effect of said drug candidates by measuring the amount of protofibrils bound to the antibody by measuring the signal generated by the agent.
Additionally provided herein is a method of diagnosing or monitoring Alzheimer's disease (AD) or Down's syndrome, comprising the steps of:
-labelling the antibody according to any one of claims 1-3 or in the composition according to claim 4 with an agent that can generate a measurable signal, 15b -administering said antibody to a sample taken from a subject or administering a non-therapeutic amount of said antibody to the subject, the subject having or suspected of having AD or Down's syndrome, -measuring the amount of protofibrils bound to the antibody by measuring the signal generated by the agent, wherein the presence of protofibrils is indicative of Alzheimer's disease or Down's syndrome.
All percentages in the description relates to percent volume, unless stated otherwise.
4. DESCRIPTION OF THE DRAWINGS
Figure 1. Size exclusion chromatography (SEC) of Human Monomer A1340, Protofibr)l Aj342Arc, Protofibrjl LutA1342 and FIbrjl wtAJ342 preparations Human A13 monomers and A13 protofibrils are eluting in 19-20 minutes and at 12-13 minutes, respectively. The protofibril preparations (B and C) are essentially free (<3%) from contamination of other conformational Af3 forms.
The analysis of the fibril preparation (D) was done after centrifugation at 17.900 x g for 5 minutes at =
room temp. The supernatant was analysed demonstrating the almost complete absence of any soluble Ap forms in the fibril preparation.
Figure 2. Stability study of protofibrils The stability of Protofibril AP42Arc and Protofibril wt42 preparations was measured by SEC. A conversion of protofibrils to fibrils was assessed by a decrease in the protofibril peak area (decreased absorbance (AU) at 214 nm elution time 12-13 minutes). The addition of 10-50% glycerol, 0.6% Tween-20 or storage at 0-5 C, all increased the protofibril stability significantly.
Figure 3. Titration of mouse serum after immunization with protofibril wt4/342 Mice were immunized with a protofibril wtA1342 preparation in Freund complete adjuvant (first injection) and incomplete Freund adjuvant (5-6 boosters). Blood was collected and the antibody titers against AP
protofibrils were determined. Mouse #2 and #4 showed the highest titers.
Figure 4. Sandwich-ELISA method using anti-mAb 258 for Ap protofibril determination inAb 258 was coated over night in a microtiterplate. Preparations of wtAp42 protofibrils, Ap42Are protofibrils, wtAp40 monomers and wtAP42 fibrils were added in decreasing concentrations and incubated for 1 hour at +4 C. Secondary anti-AP
antibody (6E10) was added. Finally, a detection ALP (alkaline phosphatase) conjugated antibody (anti-IgG) was added to each well. Detection was achieved by adding ALP substrate. The colour formation was measured in at 405 nm and 492 ILM.
mAb 258 bound wtA342 protofi.brils and slightly less Ap42Arc protofibrils.
No binding was observed to wtAp40 monomers. The slight binding to wtAP42 fibrils is probably due to a slight contamination with wtA342 protofibrils (see Figure 1 I)).
Figures 43 and 4C.
Titration by a sandwich-ELISA of 4 monoclonal antibodies ( 258, 7E4, 4E11 and 10F7) against wtA 342 protofibril concentration.
= 16a 5. EXAMPLES
The following examples are provided for illustration and are not intended to limit the invention to the specific examples provided.
Example: 1 Synthesis of human amyloid beta peptide (43) of different conformations Synthetic human wild type or mutant forms of AI31-42 or AI31-40 peptides were purchased from Polypeptide Laboratories GmbH. The peptides had been synthesized by a standard solid phase peptide synthesis procedure. The peptides were subsequently purified with RP-HPLC to a purity in the range of 90-95%.
Alternative vendors producing A13 peptides with similar purity are possible to use as well.
Synthesis of human wild type 401-40 monomers A synthetic wtAi31-40 peptide was dissolved in 1 volumes of 10 mM NaOH pH>10, and 1 volume of cold 2 x PBS (pH 7-8) to a concentration of 50 uM. The wtAI31-monomer preparation was centrifuged at 17.900 x g at +40C for 5 minutes prior to analysis (Figure 1).
Synthesis of human wild type 46.1-42 protofibrils A synthetic wtAI31-42 peptide was dissolved in 9 volumes of 10 mM NaOH pH>10, vortexed for 2 minutes and diluted with 1 volume of 10 x PBS (pH 7-8). The final peptide concentration was at this point 443 uM. The peptide was further incubated over night at 37 C. After the overnight incubation, the peptide was further diluted with PBS to 50 uM. The sample was centrifuged for 17.900 x g for 5 minutes prior to analysis and immunisation.
Synthesis of human 401-42Arc protofibrils A synthetic Ai31-42Arc (E22G) peptide was dissolved in 1 volumes of 10 mM NaOH
pH>10 and 1 volume cold 2 x PBS (pH 7-8) to a final peptide concentration of uM. The A1-42Arc protofibrils were formed immediately and the A31-42Arc protofibrils were stabilized by keeping the solution at 0-4 C before analysis or immunization. The sample was centrifuged at 17.000 x g for 5 minutes at +4 C
prior to analysis. Alternative ways to stabilize the A31-42Arc protofibrils were to add glycerol to a final concentration of 5-50 % or to add Tween-20 to a final concentration of 0.6%.
Synthesis of human wild type Ai61-42 fibrils A synthetic wtAI31-42 peptide was dissolved in 1 volumes of double distilled water, vortexed for 2 minutes and diluted with 1 volume of 2 x PBS (pH 7-8) and vortexed again for 2 minutes. The final peptide concentration at this point was 50 uM.
The wtA131-42 protofibril preparation was incubated at 37 C, for 48 hours before analysis. The sample was centrifuged at 17.900 x g for 5 minutes prior to SEC
analysis. The supernatant was analysed after centrifugation. No centrifugation was performed when A(31-42 fibril preparations were analysed by ELISA or dot blotting.
Analysis of A/3 preparation by Size Exclusion Chromatography (SEC) A Merck Hitachi D-7000 HPLC LaChroxesystem, having a diod array detector (DAD) model L-7455 and a model L-7100 pump, was used for the chromatographic analysis of protofibril preparations in combination with a Superdex 75 PC3.2/30 column (Amersham Pharmacia Biotech, Uppsala, Sweden). The chromatographic system separates Ap monomers from protofibrils, which are eluting at the void volume of the column. The column was equilibrated with 50 mM Na2HPO4 =
NaH2PO4 (pH 7.4) with 0.15 M NaC1 (PBS) and 0.6% Tween 20 and eluted with the same buffer at a flow rate of 0.08 m1/min (pressure was 5-6 bars) at ambient temperature (220C). Ten (10 ul) of a 50 uM-100 uM AP sample was subjected analysis using a wavelength scan between 200-400 run. Tween-20 was added to the sample to give a final concentration of 0.6% prior to chromatography. Data was extracted from measurements at 214 and 280 nm. Peak areas were integrated using Merck Hitachi model D-7000 Chromatography Data Station Software. Figure 1 shows chromatograms of wtAf31-40 monomer, wtAP1-42 protofibril, A(31-42Arc protofibril and wtA[31-42 fibril preparations.
Each preparation was essentially free (< 3%) of other contaminating conformational Af3 forms except the wtA31-40 monomer preparation which contained 6.4 %
protofibrils (elution time 12-13 minutes).
Example 2: Protofibrils specific monoclonal antibody development.
A standard procedure was used for monoclonal development. Mice were injected with wtA131-42 protofibril preparation. Alternatively, A(31-42Arc protofibrils could be used. Every wtA431-42 protofibril batch was assayed by SEC and Congo Red (binds (3-sheet structures in proteins) before immunisation to ascertain protofibril purity and that the preparation contained (3-sheet structure. The procedure used to immunise mice was a standard protocol involving s.c injections in the presence of Freund adjuvant. Each of six mice were immunized with 10 ug wtA131-42 protofibrils and subsequently boostered with 30 ug. The sample was mixed 1:1 with Freund complete adjuvant prior to the first injection. For subsequent 5 booster injections incomplete Freund adjuvant was used. Mouse n was not immunized (control). Mice were bleed and blood collected for antibody titer determinations (Figure 3). Mice were given one more booster (3Oug) and then sacrificed and the spleen collected for hybrid= development. The hybridom preparation method used was according to standard procedure (Harlow 1988).
Example 3: Screening for wt/01-42 protofibril specific antibodies An ELISA method was developed where by hybridom supernatants were screened for antibodies that bind Af31-42 protofibrils. Hybridom supernatant #258 showed high protofibril specificity (Figure 3). The hybridom #258 was reseeded and screened again to ascertain a homogenous cell line. The monoclonal antibody that was produced from the #258 hybridom was defined as monoclonal antibody 258 (mAb258). Alternatively, screening (binding to AIS
protofibrils but not to A1S monomers or fibrils) can be performed against an antibody phage display library, where the library has been made from RNA
isolated from animals immunized with protofibril.
Example 4. Characterization of mAb 258 by Western blot analysis.
The aim of the experiment was to determine if mAb 258 cross-reacts with wild type human amyloid precursor protein (wtAPP) or mutated human APP, APPswe, APP awe-arc (Nils berth 2001, Mullan 1992) all of which contains uncleaved A131-42. Cells were transfected with plasmids expressing human wtAPP, APPswe and APPswe-arc. Cells were subsequently harvested and solubilized and cellular proteins separated by SDS-PAGE and transferred to nitrocellulose filter papers and subsequently incubated with either mAb 258 or mAb 6E10. Specific binding of these antibodies to separated cellular proteins was detected by incubating the filter papers in a secondary anti-mouse IgG/IgM antibody solution and subsequent developed by incubation with Pierce super signaTMl (art nr 34080-P) and a light sensitive film.
mAb 258 showed no binding to wtAPP, APPswe or APPswe-arc nor to wtA(340 monomer. The commercial mAb 6E10 bound all these forms.
Example 5: Sandwich ELISA for protofibril characterization and determinations The specificity of mAb 258 was determined by a sandwich-ELISA.
An 96-well ELISA plate was coated with mAb 258 over night at +4 C. After coating, wells were blocked with BSA for 1 hour at room temp. AP samples i.e wtA340 monomers, wtA1342 protofibrils, wtAP42-Arc protofibrils wtA342 fibrils, were added to the microtiterplate in 5 x dilutions starting with 10 ug/ral. Samples were incubated for 1 hour at +40C, after which 10 ng/well of a commercial secondary antibody, 6E10 (Signet) was added and incubated for 1 hour at room temp.
Detection was achieved by incubation with a commercial ALP-conjugated anti-IgG
antibody for 1 hour at room temp. and subsequent incubation with the substrate at room temp. for one hour according to the manufacturer's procedure. Samples were read in a microtiterplate reader (Spectra mar190 Molecular Devices, Sunyvale, USA) at 405 nm and 492 rim. Figure 4A.
mAb 258 showed little or no cross-reactivity towards wtAP40 monomers or wtA042 fibrils. Concentrations of wtAP42 protofibrils down to 10 ng/ral were measurable.
Binding of an anti-A1342arc protofibril specific antibody (7E4)( A1342arc in protofibril conformation was used as a antigen during immunization) was measured in the sandwich-ELISA coated with increasing concentrations of wtA342 protofibrils.
Detection was achieved by either an Ap -specific mAb (1C3) as a secondary detection antibody (Figure 4B) or by the commercial mAb 6E10, as secondary antibody (Figure 4C). Strong binding of mAb 7E4 was achieved to wtA042 protofibrils. Concentration levels as low as 2-5 ng/ml of wtAP42 protofibrils were measurable. The monoclonal antibodies 4E11 and 10F7show less strong binding to wtAP42 protofibrils (Figure 4B and 4C).
REFERENCES:
Axelman K., et.al., Neurol., 51, 1193-1197,1994 Bard F. et.al., Nature medicine, 6, 916-919, 2000 Cal, X-D. et.al., Science, 259, 514-516, 1993 Citron, M. et.al., Nature, 360, 672-674, 1992 DeMarco et.al., Proc. Natl.Acad.Sci., 101, 2293-2298, 2004 Dodard J-C. et.al. Nature medicine, 5 452-457, 2002 Glenner et.al., Biochem. Biophys. Res. Commun. 120, 885-890, 1984 Hardy, J. et.al., Nature Genet., 1, 233-234, 1992 Hartley D.M. et.al., J. Neuroscience 19, 8876-8884, 1999 Harlow E. et.al., Antibodies: A Laboratory Manual (Cold Spring Harbor) Lab.
Press, Plainview, NY, 1988 Hoshi M. et.al., Proc. Natl. Acad. Sci., 100, 6370-6375, 2003 Janus C.V. et.al., Nature, 408, 979-982, 2000 Johnston, J. et.al., FEBS Lett., 354, 274-278, 1994 Kayed R. et.al., Science 300, 486-489, 2003 Klyubin et al., J. Physiol 551P, C32, commun., 2003 Lambert M.P. et.al., Proc. Natl. Acad. Sc., 95, 64486453,1998 Lambert M.P. et.al., J.Neurochemistry, 79,595-605, 2001 Lannfelt, L., et.al., Neurosci. Lett., 168, 254-256, 1994 Larmfelt L. et.al., Neurosci Lett.,199, 203-206,1995 Masters et.al., Proc. Natl.Acad.Sci., 82, 4245-4249, 1985 McKhann, G., et.al., Neurology, 34, 939-944, 1984 Morgan D. et.al., Nature, 408, 982-985,,2000 Motter R. Et. al., Ann. Neurol., 38, 643-648, 1995 Mullan M. et.al., Nature Genet. 1, 345-347, 1992 Nicoll J.A.R. et.al., Nature medicine, 1-5, on line publ. 17 mars, 2003 Nilsberth C. et.al., Nat. Neurosci. 4, 887-893, 2001 Nilsson L. et. al., Swedish patent application 0400707-6, 2004 0-Nuallain B. et.al., PNAS 99,1485-1490, 2002 PirttilA et.al., J. Neurol. Sci., 127, 90-95, 1994 Scheuner D. et.al., Nature Med., 2, 864-869, 1996 Selkoe D. J., Ann. Rev. Cell Biol. 10,373-403, 1994 Selkoe D. J., Annu. Rev. Neurosci. 17, 489-517, 1994 Seubert P. et.al., Nature, 359, 325-327, 1992 Shenk et al., Nature, 400, 173-177, 1999 Sigurdsen E.M. et.al., Am.J.Pathol.,105, 439-447, 2001 Sthilerman M. et.al., Biochemistry 41, 3855-3860, 2002 Stine et.al., J. Protein Chem. 15, 193-203,1996 Walsh D.M. etal., J.Biol.Chem. 274, 25945-25952, 1999 Walsh D.M. et.al., Nature 416, 535-539, 2001 Weiner H.L. et.al., Ann.Neurol. 48, 567-579, 2000
In said method of prevention or treatment of Alzheimer's disease or Down's a subject having or suspected of having Alzheimer's disease, Down's syndrome, Lewybody dementia, vascular dementia, and other neurodegenerative disorders, is administered the antibody or composition according to the present invention.
The invention also provides a technique whereby anti-A13protofibril antibodies can be used to identify and select for epitopes present on AP protofibrils but less on AP
monomers and Ap fibrils or other A13 conformational forms. The method is general and is applicable to other amyloids forming protofibrils such as, but not limited to, islet amyloid protein peptide (IAPP, amylin) associated with Type-2 diabetes ,prion protein (PrP), alpha-synuclein (Parkinson). Considering the central role of amyloid beta (A13) protofibrils in Alzheimer's disease, these antibodies can be used to diagnose or treat Alzheimer's disease. There is a need for a method that specifically can determine protofibrils in different human and animal tissues such as cerebral spinal fluid (CSF), plasma, blood, urine and brain tissue, but is not limited to these tissues. Such a method could be used as a diagnostic method for Alzheimer's disease but also for similar diseases that forms amyloid protofibrils including Parkinson (alpha-synuclein) (Sthilerman 2002), Type-2 diabetes (Islet amyloid polypeptide, IAPP) (W003/ 092619 A2), and Creutzfeldt-Jacob Disease and the corresponding animal disease called mad cow disease (Prion protein) (DeMarco 2004) , but is not limited to these diseases.
According to another aspect, the present invention relates to the use of anti-protofibril antibodies for in vitro or in vivo screening of substances that inhibit or modulate AP protoflbril levels and/or activity in cell cultures or animal models, being potential Alzheimer drugs. Suitable screening systems would be, but are not limited to, cell cultures (HEC or neuroblastoma cells) or for example the Thy-APPSweArc transgenic mouse model, (Nilsson L. et al. Swedish patent application 0400707-6, 2004) that expresses human Amyloid Precursor Protein (APP) with the Arctic mutation (E693G) providing increased production of A13 protofibrils.
Alzheimer drug candidates can be administered to these cell cultures or transgenic animal models and their effects on AP protofibril levels measured by an immunoassay, using an anti-AP protofibril antibody as reagent. Such method would be ideally suitable for identifying potent Alzheimer drug candidates.
Said method for in vitro or in vivo screening of substances that inhibit or modulate AP protofibril levels and/or activity in cell cultures or animal models, comprises the steps of administering potential drug candidates to a cell culture or an animal model, administering the antibody according to any the present invention, labelled with an agent that can generate a measurable signal, to said cell culture or animal model, evaluating the effect of said drug candidates by measuring the amount of protofibrils bound to the antibody by measuring the signal generated by the agent.
According to another aspect, the present invention relates to a method of detecting Ap protofibrils in vitro, comprising labelling the according to the present invention with an agent that can generate a measurable signal, contacting said antibody or the composition comprising the antibody with a biological sample suspected of containing soluble protofibrils, measuring the amount of protofibrils bound to the antibody by measuring the signal generated by the agent. Said method may be an immunoassay. The biological samples tested may be selected from plasma, CSF, brain and other tissues of animal or human origin. The labelling includes labelling with radioactive markers, DNA, fluorescent molecules, enzymes which converts a substrate such that its absorbance can be measured.
Provided herein is an isolated monoclonal antibody or antigen-binding fragment thereof that is specific for amyloid beta peptide (AP) protofibrils, and binds and A340 wild-type protofibril and A1342 and A1340 arc protofibril with low A(340 and A342 monomer cross-reactivity.
15a Also provided herein is a method of detecting amyloid beta peptide (Am protofibrils in vitro, comprising:
-labelling the antibody according to any one of claims 1-3 or in the composition according to claim 4 with an agent that can generate a measurable signal, -contacting said antibody or the composition comprising the antibody with a biological sample suspected of containing soluble protofibrils, -measuring the amount of protofibrils bound to the antibody by measuring the signal generated by the agent.
Further provided herein is a method for in vitro or in vivo screening of substances that inhibit amyloid beta peptide (A3) protofibril levels and/or activity in cell cultures or animal models genetically engineered to have high levels of amyloid beta peptide (AP ) protofibrils, comprising the steps of:
-administering potential drug candidates to a cell culture or an animal model, -administering an antibody according to any one of claims 1-3 or in the composition according to claim 4, labelled with an agent that can generate a measurable signal, to said cell culture or animal model -evaluating the effect of said drug candidates by measuring the amount of protofibrils bound to the antibody by measuring the signal generated by the agent.
Additionally provided herein is a method of diagnosing or monitoring Alzheimer's disease (AD) or Down's syndrome, comprising the steps of:
-labelling the antibody according to any one of claims 1-3 or in the composition according to claim 4 with an agent that can generate a measurable signal, 15b -administering said antibody to a sample taken from a subject or administering a non-therapeutic amount of said antibody to the subject, the subject having or suspected of having AD or Down's syndrome, -measuring the amount of protofibrils bound to the antibody by measuring the signal generated by the agent, wherein the presence of protofibrils is indicative of Alzheimer's disease or Down's syndrome.
All percentages in the description relates to percent volume, unless stated otherwise.
4. DESCRIPTION OF THE DRAWINGS
Figure 1. Size exclusion chromatography (SEC) of Human Monomer A1340, Protofibr)l Aj342Arc, Protofibrjl LutA1342 and FIbrjl wtAJ342 preparations Human A13 monomers and A13 protofibrils are eluting in 19-20 minutes and at 12-13 minutes, respectively. The protofibril preparations (B and C) are essentially free (<3%) from contamination of other conformational Af3 forms.
The analysis of the fibril preparation (D) was done after centrifugation at 17.900 x g for 5 minutes at =
room temp. The supernatant was analysed demonstrating the almost complete absence of any soluble Ap forms in the fibril preparation.
Figure 2. Stability study of protofibrils The stability of Protofibril AP42Arc and Protofibril wt42 preparations was measured by SEC. A conversion of protofibrils to fibrils was assessed by a decrease in the protofibril peak area (decreased absorbance (AU) at 214 nm elution time 12-13 minutes). The addition of 10-50% glycerol, 0.6% Tween-20 or storage at 0-5 C, all increased the protofibril stability significantly.
Figure 3. Titration of mouse serum after immunization with protofibril wt4/342 Mice were immunized with a protofibril wtA1342 preparation in Freund complete adjuvant (first injection) and incomplete Freund adjuvant (5-6 boosters). Blood was collected and the antibody titers against AP
protofibrils were determined. Mouse #2 and #4 showed the highest titers.
Figure 4. Sandwich-ELISA method using anti-mAb 258 for Ap protofibril determination inAb 258 was coated over night in a microtiterplate. Preparations of wtAp42 protofibrils, Ap42Are protofibrils, wtAp40 monomers and wtAP42 fibrils were added in decreasing concentrations and incubated for 1 hour at +4 C. Secondary anti-AP
antibody (6E10) was added. Finally, a detection ALP (alkaline phosphatase) conjugated antibody (anti-IgG) was added to each well. Detection was achieved by adding ALP substrate. The colour formation was measured in at 405 nm and 492 ILM.
mAb 258 bound wtA342 protofi.brils and slightly less Ap42Arc protofibrils.
No binding was observed to wtAp40 monomers. The slight binding to wtAP42 fibrils is probably due to a slight contamination with wtA342 protofibrils (see Figure 1 I)).
Figures 43 and 4C.
Titration by a sandwich-ELISA of 4 monoclonal antibodies ( 258, 7E4, 4E11 and 10F7) against wtA 342 protofibril concentration.
= 16a 5. EXAMPLES
The following examples are provided for illustration and are not intended to limit the invention to the specific examples provided.
Example: 1 Synthesis of human amyloid beta peptide (43) of different conformations Synthetic human wild type or mutant forms of AI31-42 or AI31-40 peptides were purchased from Polypeptide Laboratories GmbH. The peptides had been synthesized by a standard solid phase peptide synthesis procedure. The peptides were subsequently purified with RP-HPLC to a purity in the range of 90-95%.
Alternative vendors producing A13 peptides with similar purity are possible to use as well.
Synthesis of human wild type 401-40 monomers A synthetic wtAi31-40 peptide was dissolved in 1 volumes of 10 mM NaOH pH>10, and 1 volume of cold 2 x PBS (pH 7-8) to a concentration of 50 uM. The wtAI31-monomer preparation was centrifuged at 17.900 x g at +40C for 5 minutes prior to analysis (Figure 1).
Synthesis of human wild type 46.1-42 protofibrils A synthetic wtAI31-42 peptide was dissolved in 9 volumes of 10 mM NaOH pH>10, vortexed for 2 minutes and diluted with 1 volume of 10 x PBS (pH 7-8). The final peptide concentration was at this point 443 uM. The peptide was further incubated over night at 37 C. After the overnight incubation, the peptide was further diluted with PBS to 50 uM. The sample was centrifuged for 17.900 x g for 5 minutes prior to analysis and immunisation.
Synthesis of human 401-42Arc protofibrils A synthetic Ai31-42Arc (E22G) peptide was dissolved in 1 volumes of 10 mM NaOH
pH>10 and 1 volume cold 2 x PBS (pH 7-8) to a final peptide concentration of uM. The A1-42Arc protofibrils were formed immediately and the A31-42Arc protofibrils were stabilized by keeping the solution at 0-4 C before analysis or immunization. The sample was centrifuged at 17.000 x g for 5 minutes at +4 C
prior to analysis. Alternative ways to stabilize the A31-42Arc protofibrils were to add glycerol to a final concentration of 5-50 % or to add Tween-20 to a final concentration of 0.6%.
Synthesis of human wild type Ai61-42 fibrils A synthetic wtAI31-42 peptide was dissolved in 1 volumes of double distilled water, vortexed for 2 minutes and diluted with 1 volume of 2 x PBS (pH 7-8) and vortexed again for 2 minutes. The final peptide concentration at this point was 50 uM.
The wtA131-42 protofibril preparation was incubated at 37 C, for 48 hours before analysis. The sample was centrifuged at 17.900 x g for 5 minutes prior to SEC
analysis. The supernatant was analysed after centrifugation. No centrifugation was performed when A(31-42 fibril preparations were analysed by ELISA or dot blotting.
Analysis of A/3 preparation by Size Exclusion Chromatography (SEC) A Merck Hitachi D-7000 HPLC LaChroxesystem, having a diod array detector (DAD) model L-7455 and a model L-7100 pump, was used for the chromatographic analysis of protofibril preparations in combination with a Superdex 75 PC3.2/30 column (Amersham Pharmacia Biotech, Uppsala, Sweden). The chromatographic system separates Ap monomers from protofibrils, which are eluting at the void volume of the column. The column was equilibrated with 50 mM Na2HPO4 =
NaH2PO4 (pH 7.4) with 0.15 M NaC1 (PBS) and 0.6% Tween 20 and eluted with the same buffer at a flow rate of 0.08 m1/min (pressure was 5-6 bars) at ambient temperature (220C). Ten (10 ul) of a 50 uM-100 uM AP sample was subjected analysis using a wavelength scan between 200-400 run. Tween-20 was added to the sample to give a final concentration of 0.6% prior to chromatography. Data was extracted from measurements at 214 and 280 nm. Peak areas were integrated using Merck Hitachi model D-7000 Chromatography Data Station Software. Figure 1 shows chromatograms of wtAf31-40 monomer, wtAP1-42 protofibril, A(31-42Arc protofibril and wtA[31-42 fibril preparations.
Each preparation was essentially free (< 3%) of other contaminating conformational Af3 forms except the wtA31-40 monomer preparation which contained 6.4 %
protofibrils (elution time 12-13 minutes).
Example 2: Protofibrils specific monoclonal antibody development.
A standard procedure was used for monoclonal development. Mice were injected with wtA131-42 protofibril preparation. Alternatively, A(31-42Arc protofibrils could be used. Every wtA431-42 protofibril batch was assayed by SEC and Congo Red (binds (3-sheet structures in proteins) before immunisation to ascertain protofibril purity and that the preparation contained (3-sheet structure. The procedure used to immunise mice was a standard protocol involving s.c injections in the presence of Freund adjuvant. Each of six mice were immunized with 10 ug wtA131-42 protofibrils and subsequently boostered with 30 ug. The sample was mixed 1:1 with Freund complete adjuvant prior to the first injection. For subsequent 5 booster injections incomplete Freund adjuvant was used. Mouse n was not immunized (control). Mice were bleed and blood collected for antibody titer determinations (Figure 3). Mice were given one more booster (3Oug) and then sacrificed and the spleen collected for hybrid= development. The hybridom preparation method used was according to standard procedure (Harlow 1988).
Example 3: Screening for wt/01-42 protofibril specific antibodies An ELISA method was developed where by hybridom supernatants were screened for antibodies that bind Af31-42 protofibrils. Hybridom supernatant #258 showed high protofibril specificity (Figure 3). The hybridom #258 was reseeded and screened again to ascertain a homogenous cell line. The monoclonal antibody that was produced from the #258 hybridom was defined as monoclonal antibody 258 (mAb258). Alternatively, screening (binding to AIS
protofibrils but not to A1S monomers or fibrils) can be performed against an antibody phage display library, where the library has been made from RNA
isolated from animals immunized with protofibril.
Example 4. Characterization of mAb 258 by Western blot analysis.
The aim of the experiment was to determine if mAb 258 cross-reacts with wild type human amyloid precursor protein (wtAPP) or mutated human APP, APPswe, APP awe-arc (Nils berth 2001, Mullan 1992) all of which contains uncleaved A131-42. Cells were transfected with plasmids expressing human wtAPP, APPswe and APPswe-arc. Cells were subsequently harvested and solubilized and cellular proteins separated by SDS-PAGE and transferred to nitrocellulose filter papers and subsequently incubated with either mAb 258 or mAb 6E10. Specific binding of these antibodies to separated cellular proteins was detected by incubating the filter papers in a secondary anti-mouse IgG/IgM antibody solution and subsequent developed by incubation with Pierce super signaTMl (art nr 34080-P) and a light sensitive film.
mAb 258 showed no binding to wtAPP, APPswe or APPswe-arc nor to wtA(340 monomer. The commercial mAb 6E10 bound all these forms.
Example 5: Sandwich ELISA for protofibril characterization and determinations The specificity of mAb 258 was determined by a sandwich-ELISA.
An 96-well ELISA plate was coated with mAb 258 over night at +4 C. After coating, wells were blocked with BSA for 1 hour at room temp. AP samples i.e wtA340 monomers, wtA1342 protofibrils, wtAP42-Arc protofibrils wtA342 fibrils, were added to the microtiterplate in 5 x dilutions starting with 10 ug/ral. Samples were incubated for 1 hour at +40C, after which 10 ng/well of a commercial secondary antibody, 6E10 (Signet) was added and incubated for 1 hour at room temp.
Detection was achieved by incubation with a commercial ALP-conjugated anti-IgG
antibody for 1 hour at room temp. and subsequent incubation with the substrate at room temp. for one hour according to the manufacturer's procedure. Samples were read in a microtiterplate reader (Spectra mar190 Molecular Devices, Sunyvale, USA) at 405 nm and 492 rim. Figure 4A.
mAb 258 showed little or no cross-reactivity towards wtAP40 monomers or wtA042 fibrils. Concentrations of wtAP42 protofibrils down to 10 ng/ral were measurable.
Binding of an anti-A1342arc protofibril specific antibody (7E4)( A1342arc in protofibril conformation was used as a antigen during immunization) was measured in the sandwich-ELISA coated with increasing concentrations of wtA342 protofibrils.
Detection was achieved by either an Ap -specific mAb (1C3) as a secondary detection antibody (Figure 4B) or by the commercial mAb 6E10, as secondary antibody (Figure 4C). Strong binding of mAb 7E4 was achieved to wtA042 protofibrils. Concentration levels as low as 2-5 ng/ml of wtAP42 protofibrils were measurable. The monoclonal antibodies 4E11 and 10F7show less strong binding to wtAP42 protofibrils (Figure 4B and 4C).
REFERENCES:
Axelman K., et.al., Neurol., 51, 1193-1197,1994 Bard F. et.al., Nature medicine, 6, 916-919, 2000 Cal, X-D. et.al., Science, 259, 514-516, 1993 Citron, M. et.al., Nature, 360, 672-674, 1992 DeMarco et.al., Proc. Natl.Acad.Sci., 101, 2293-2298, 2004 Dodard J-C. et.al. Nature medicine, 5 452-457, 2002 Glenner et.al., Biochem. Biophys. Res. Commun. 120, 885-890, 1984 Hardy, J. et.al., Nature Genet., 1, 233-234, 1992 Hartley D.M. et.al., J. Neuroscience 19, 8876-8884, 1999 Harlow E. et.al., Antibodies: A Laboratory Manual (Cold Spring Harbor) Lab.
Press, Plainview, NY, 1988 Hoshi M. et.al., Proc. Natl. Acad. Sci., 100, 6370-6375, 2003 Janus C.V. et.al., Nature, 408, 979-982, 2000 Johnston, J. et.al., FEBS Lett., 354, 274-278, 1994 Kayed R. et.al., Science 300, 486-489, 2003 Klyubin et al., J. Physiol 551P, C32, commun., 2003 Lambert M.P. et.al., Proc. Natl. Acad. Sc., 95, 64486453,1998 Lambert M.P. et.al., J.Neurochemistry, 79,595-605, 2001 Lannfelt, L., et.al., Neurosci. Lett., 168, 254-256, 1994 Larmfelt L. et.al., Neurosci Lett.,199, 203-206,1995 Masters et.al., Proc. Natl.Acad.Sci., 82, 4245-4249, 1985 McKhann, G., et.al., Neurology, 34, 939-944, 1984 Morgan D. et.al., Nature, 408, 982-985,,2000 Motter R. Et. al., Ann. Neurol., 38, 643-648, 1995 Mullan M. et.al., Nature Genet. 1, 345-347, 1992 Nicoll J.A.R. et.al., Nature medicine, 1-5, on line publ. 17 mars, 2003 Nilsberth C. et.al., Nat. Neurosci. 4, 887-893, 2001 Nilsson L. et. al., Swedish patent application 0400707-6, 2004 0-Nuallain B. et.al., PNAS 99,1485-1490, 2002 PirttilA et.al., J. Neurol. Sci., 127, 90-95, 1994 Scheuner D. et.al., Nature Med., 2, 864-869, 1996 Selkoe D. J., Ann. Rev. Cell Biol. 10,373-403, 1994 Selkoe D. J., Annu. Rev. Neurosci. 17, 489-517, 1994 Seubert P. et.al., Nature, 359, 325-327, 1992 Shenk et al., Nature, 400, 173-177, 1999 Sigurdsen E.M. et.al., Am.J.Pathol.,105, 439-447, 2001 Sthilerman M. et.al., Biochemistry 41, 3855-3860, 2002 Stine et.al., J. Protein Chem. 15, 193-203,1996 Walsh D.M. etal., J.Biol.Chem. 274, 25945-25952, 1999 Walsh D.M. et.al., Nature 416, 535-539, 2001 Weiner H.L. et.al., Ann.Neurol. 48, 567-579, 2000
Claims (10)
1. An isolated monoclonal antibody or antigen-binding fragment thereof that is specific for amyloid beta peptide (A.beta.) protofibrils, and binds Ap42 and A.beta.40 wild-type protofibril and A.beta.42 and A.beta.40 arc protofibril with low A.beta.40 and A.beta.42 monomer cross-reactivity.
2. The antibody according to claim 1, wherein said antibody cross-reacts less than 50% with A.beta. fibrils.
3. The antibody according to any one of claims 1-2, wherein said antibody can detect both wild type A.beta. protofibrils and Arctic A.beta.
protofibrils in an ELISA in the concentration range of 1000-10 ng/ml.
protofibrils in an ELISA in the concentration range of 1000-10 ng/ml.
4. A composition comprising one or more antibodies according to any one of claims 1-3 and a carrier or excipient.
5. A method of detecting amyloid beta peptide (A.beta.) protofibrils in vitro, comprising:
- labelling the antibody according to any one of claims 1-3 or in the composition according to claim 4 with an agent that can generate a measurable signal, - contacting said antibody or the composition comprising the antibody with a biological sample suspected of containing soluble protofibrils, -measuring the amount of protofibrils bound to the antibody by measuring the signal generated by the agent.
- labelling the antibody according to any one of claims 1-3 or in the composition according to claim 4 with an agent that can generate a measurable signal, - contacting said antibody or the composition comprising the antibody with a biological sample suspected of containing soluble protofibrils, -measuring the amount of protofibrils bound to the antibody by measuring the signal generated by the agent.
6. The method according to claim 5, wherein said biological sample is selected from plasma, cerebrospinal fluid (CSF), brain and other tissues of animal or human origin.
7. The method according to claim 5, wherein the labelling includes labelling with radioactive markers, fluorescent molecules, or enzymes which convert a substrate such that its absorbance can be measured.
8. Use of the antibody according to any one of claims 1-3 or the composition according to claim 4 for prevention or treatment of Alzheimer's disease, Down's syndrome, Lewybody dementia, or vascular dementia in a subject having or suspected of having Alzheimer's disease, Down's syndrome, Lewybody dementia, or vascular dementia.
9. A method for in vitro or in vivo screening of substances that inhibit amyloid beta peptide (A.beta.) protofibril levels and/or activity in cell cultures or animal models genetically engineered to have high levels of amyloid beta peptide (A.beta.) protofibrils, comprising the steps of:
- administering potential drug candidates to a cell culture or an animal model, - administering an antibody according to any one of claims 1-3 or in the composition according to claim 4, labelled with an agent that can generate a measurable signal, to said cell culture or animal model - evaluating the effect of said drug candidates by measuring the amount of protofibrils bound to the antibody by measuring the signal generated by the agent.
- administering potential drug candidates to a cell culture or an animal model, - administering an antibody according to any one of claims 1-3 or in the composition according to claim 4, labelled with an agent that can generate a measurable signal, to said cell culture or animal model - evaluating the effect of said drug candidates by measuring the amount of protofibrils bound to the antibody by measuring the signal generated by the agent.
10. A method of diagnosing or monitoring Alzheimer's disease (AD) or Down's syndrome, comprising the steps of:
- labelling the antibody according to any one of claims 1-3 or in the composition according to claim 4 with an agent that can generate a measurable signal, - administering said antibody to a sample taken from a subject or administering a non-therapeutic amount of said antibody to the subject, the subject having or suspected of having AD or Down's syndrome, - measuring the amount of protofibrils bound to the antibody by measuring the signal generated by the agent, wherein the presence of protofibrils is indicative of Alzheimer's disease or Down's syndrome.
- labelling the antibody according to any one of claims 1-3 or in the composition according to claim 4 with an agent that can generate a measurable signal, - administering said antibody to a sample taken from a subject or administering a non-therapeutic amount of said antibody to the subject, the subject having or suspected of having AD or Down's syndrome, - measuring the amount of protofibrils bound to the antibody by measuring the signal generated by the agent, wherein the presence of protofibrils is indicative of Alzheimer's disease or Down's syndrome.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0401601A SE0401601D0 (en) | 2004-06-21 | 2004-06-21 | Protofibril specific antibodies and uses thereof |
SE0401601-0 | 2004-06-21 | ||
PCT/SE2005/000993 WO2005123775A1 (en) | 2004-06-21 | 2005-06-21 | Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2570130A1 CA2570130A1 (en) | 2005-12-29 |
CA2570130C true CA2570130C (en) | 2016-02-23 |
Family
ID=32906833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2570130A Active CA2570130C (en) | 2004-06-21 | 2005-06-21 | Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof |
Country Status (13)
Country | Link |
---|---|
US (4) | US8106164B2 (en) |
EP (1) | EP1781703B1 (en) |
AU (1) | AU2005254928B2 (en) |
CA (1) | CA2570130C (en) |
CY (1) | CY1116776T1 (en) |
DK (1) | DK1781703T3 (en) |
ES (1) | ES2537001T3 (en) |
HU (1) | HUE025628T2 (en) |
PL (1) | PL1781703T3 (en) |
PT (1) | PT1781703E (en) |
SE (1) | SE0401601D0 (en) |
SI (1) | SI1781703T1 (en) |
WO (1) | WO2005123775A1 (en) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002003911A2 (en) | 2000-07-07 | 2002-01-17 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
WO2005025516A2 (en) * | 2003-09-12 | 2005-03-24 | The Regents Of The University Of California | Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates |
WO2010011999A2 (en) | 2008-07-25 | 2010-01-28 | The Regents Of The University Of California | Methods and compositions for eliciting an amyloid-selective immune response |
DE10303974A1 (en) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid β (1-42) oligomers, process for their preparation and their use |
US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
SE0401601D0 (en) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
AU2006319358B2 (en) | 2005-11-30 | 2012-01-19 | AbbVie Deutschland GmbH & Co. KG | Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
RS53270B2 (en) | 2005-11-30 | 2018-05-31 | Abbvie Deutschland | Monoclonal antibodies against amyloid beta protein and uses thereof |
EP1963363A2 (en) | 2005-11-30 | 2008-09-03 | Abbott Laboratories | Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins |
NO345996B1 (en) * | 2005-12-12 | 2021-12-13 | Ac Immune Sa | A beta 1-42-specific monoclonal antibodies with therapeutic properties. |
CN1329413C (en) * | 2006-01-23 | 2007-08-01 | 南京医科大学 | Antibody for treating or preventing senile dementia, its expression vector and application in drug preparation |
WO2007108756A1 (en) * | 2006-03-23 | 2007-09-27 | Bioarctic Neuroscience Ab | Improved protofibril selective antibodies and the use thereof |
PL2468770T3 (en) * | 2006-07-14 | 2018-07-31 | Ac Immune S.A. | Humanized antibody against amyloid beta. |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | Isolated human antibody which is capable of selectively recognizing a neoepitope of a disorder-associated protein, a polynucleotide encoding the antibody, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or the vector, a composition comprising the antibody and methods and uses associated therewith |
EP2426143B1 (en) * | 2007-01-05 | 2017-06-28 | University of Zurich | Method of providing disease-specific binding molecules and targets |
PL2104682T3 (en) | 2007-01-11 | 2017-03-31 | Michael Bacher | Diagnosis and treatment of alzheimer's and other neurodementing diseases |
EP2486928A1 (en) | 2007-02-27 | 2012-08-15 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
AU2008220785B2 (en) | 2007-03-01 | 2013-02-21 | Vivoryon Therapeutics N.V. | New use of glutaminyl cyclase inhibitors |
US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
PE20090329A1 (en) * | 2007-05-30 | 2009-03-27 | Abbott Lab | HUMANIZED ANTIBODIES AGAINST GLOBULOMER AB (20-42) AND ITS USES |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
SG182192A1 (en) * | 2007-06-12 | 2012-07-30 | Ac Immune Sa | Humanized antibodies to amyloid beta |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
KR20100074181A (en) * | 2007-09-13 | 2010-07-01 | 델레넥스 쎄라퓨틱스 아게 | HUMANIZED ANTIBODIES AGAINST THE β-AMYLOYD PEPTIDE |
RU2538709C2 (en) * | 2007-10-05 | 2015-01-10 | Дженентек, Инк. | Humanised antibody |
US20100297012A1 (en) * | 2007-10-05 | 2010-11-25 | Andrea Pfeifer | Humanized antibody |
ES2445590T3 (en) * | 2007-10-05 | 2014-03-04 | Genentech, Inc. | Use of anti-beta amyloid antibody in eye diseases |
JO3076B1 (en) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | Immunotherapy regimes dependent on apoe status |
MY158903A (en) * | 2007-11-16 | 2016-11-30 | Univ Rockefeller | Antibodies specific for the protofibril form of beta-amyloid protein |
PL2282758T3 (en) * | 2008-04-29 | 2019-04-30 | Bioarctic Ab | Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders |
CA2746778C (en) | 2008-12-19 | 2019-04-23 | University Of Zurich | Human anti-alpha-synuclein autoantibodies |
TWI508976B (en) * | 2009-04-21 | 2015-11-21 | Univ Rockefeller | Antibodies specific for the protofibril form of beta-amyloid protein |
FR2945538B1 (en) | 2009-05-12 | 2014-12-26 | Sanofi Aventis | HUMANIZED ANTIBODIES SPECIFIC TO THE PROTOFIBRILLARY FORM OF THE BETA-AMYLOID PEPTIDE. |
CA2765602C (en) * | 2009-06-29 | 2021-05-25 | Bioarctic Neuroscience Ab | N-terminal truncated protofibrils/oligomers for use in therapeutic and diagnostic methods for alzheimer's disease and related disorders |
EP2475428B1 (en) | 2009-09-11 | 2015-07-01 | Probiodrug AG | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
US8632776B2 (en) | 2010-02-26 | 2014-01-21 | Bioarctic Neuroscience Ab | Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for Parkinson's disease, dementia with lewy bodies and other α-synucleinopathies |
JP6026284B2 (en) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | Inhibitors of glutaminyl cyclase |
JP5688745B2 (en) | 2010-03-10 | 2015-03-25 | プロビオドルグ エージー | Heterocyclic inhibitor of glutaminyl cyclase (QC, EC 2.3.2.5) |
MX336196B (en) | 2010-04-15 | 2016-01-11 | Abbvie Inc | Amyloid-beta binding proteins. |
US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
RU2012151850A (en) * | 2010-06-04 | 2014-07-20 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Derivatives of 1- (2-Fluorobiphenyl-4-yl) Cyclopropanecarboxylic Acid for Prion Disease Therapy |
BR112013002297A2 (en) | 2010-07-30 | 2016-05-24 | Ac Immune Sa | safe and functional humanized antibodies |
WO2012024187A1 (en) | 2010-08-14 | 2012-02-23 | Abbott Laboratories | Amyloid-beta binding proteins |
AU2012229236B2 (en) | 2011-03-11 | 2017-05-18 | Beth Israel Deaconess Medical Center, Inc. | Anti-CD40 antibodies and uses thereof |
WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
WO2012142301A2 (en) | 2011-04-12 | 2012-10-18 | Quanterix Corporation | Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury |
AU2012272790B2 (en) | 2011-06-23 | 2016-10-06 | Biogen International Neuroscience Gmbh | Anti-alpha synuclein binding molecules |
GB201112056D0 (en) | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
BR112016030774A2 (en) | 2014-07-10 | 2018-01-16 | Bioarctic Neuroscience Ab | antibody or antigen binding fragment thereof, use of an antibody, methods for reducing the amount of? in an individual, for treatment and / or for prophylaxis of a disease, for measuring the amount of? and / or protein ?? aggregate in a person, and for diagnosis of a disease, and, pharmaceutical composition |
MA41115A (en) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | ALZHEIMER'S DISEASE TREATMENT PROCESS |
US11327080B2 (en) | 2015-07-21 | 2022-05-10 | BioArctic Neruoscience AB | Method for treatment of traumatic brain injury targeting aggregated peptides |
EP3906943A1 (en) | 2015-09-04 | 2021-11-10 | Primatope Therapeutics Inc. | Humanized anti-cd40 antibodies and uses thereof |
RU2019102746A (en) | 2016-07-14 | 2020-08-14 | Биоарктик Аб | PROTEIN FOR TRANSPORT TO THE BRAIN |
EP3672631B9 (en) | 2017-08-22 | 2023-06-28 | Biogen MA Inc. | Pharmaceutical compositions containing anti-beta amyloid antibodies |
ES2812698T3 (en) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Glutaminyl cyclase inhibitors |
US20210324056A1 (en) | 2018-07-24 | 2021-10-21 | Eisai R&D Management Co., Ltd. | Methods of treatment and prevention of alzheimer's disease |
CA3181207A1 (en) | 2020-06-26 | 2021-12-30 | Bioarctic Ab | A-synuclein protofibril-binding antibodies |
WO2022020680A1 (en) | 2020-07-23 | 2022-01-27 | Othair Prothena Limited | Anti-abeta antibodies |
TW202300517A (en) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | Anti-amyloid beta antibodies and uses thereof |
WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
AU2022307687A1 (en) | 2021-07-09 | 2024-01-04 | Eisai R&D Management Co., Ltd. | Biomarkers for alzheimer's disease treatment |
CA3230148A1 (en) | 2021-08-30 | 2023-03-09 | Eisai R&D Management Co., Ltd. | Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof |
TW202339794A (en) | 2022-02-02 | 2023-10-16 | 日商衛材R&D企管股份有限公司 | Methods of treatment using p-tau181 level |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5231000A (en) | 1987-10-08 | 1993-07-27 | The Mclean Hospital | Antibodies to A4 amyloid peptide |
US5753624A (en) | 1990-04-27 | 1998-05-19 | Milkhaus Laboratory, Inc. | Materials and methods for treatment of plaquing disease |
US6174916B1 (en) | 1990-04-27 | 2001-01-16 | Milkhaus Laboratory, Ltd. | Methods for treating herpes virus infections |
CA2081482C (en) | 1990-04-27 | 2000-11-21 | Ellis L. Kline | Method and composition for treatment of central nervous system disease states associated with abnormal amyloid beta protein molecular organization |
US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
ES2155099T3 (en) | 1993-10-27 | 2001-05-01 | Elan Pharm Inc | TRANSGENIC ANIMALS THAT HOST APP ALELOS THAT PRESENT A SWEDISH MUTATION. |
CA2191101C (en) | 1994-05-25 | 2001-08-07 | Ellis L. Kline | Materials and methods for treatment of plaquing diseases |
US6114133A (en) | 1994-11-14 | 2000-09-05 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41) |
US7427392B1 (en) * | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
US5786180A (en) | 1995-02-14 | 1998-07-28 | Bayer Corporation | Monoclonal antibody 369.2B specific for β A4 peptide |
US6303567B1 (en) | 1995-03-14 | 2001-10-16 | Praecis Pharmaceuticals, Inc . | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
US5817626A (en) | 1995-03-14 | 1998-10-06 | Praecis Pharmaceuticals Incorporated | Modulators of beta-amyloid peptide aggregation |
US5854215A (en) | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals Incorporated | Modulators of β-amyloid peptide aggregation |
DE69621607T2 (en) * | 1995-03-14 | 2003-01-02 | Praecis Pharm Inc | CONNECTIONS WITH AGGREGATION-MODULATING EFFECT ON THE AMYLOiD PROTEIN |
US5985242A (en) | 1995-10-27 | 1999-11-16 | Praecis Pharmaceuticals, Inc. | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
JPH09178743A (en) | 1995-12-27 | 1997-07-11 | Oriental Yeast Co Ltd | Determinationof soluble app |
WO1997041856A1 (en) | 1996-05-08 | 1997-11-13 | Massachusetts Institute Of Technology | ORGANOMETALLIC LIGANDS FOR THE LOCALIZATION AND QUANTIFICATION OF AMYLOID IN VIVO AND $i(IN VITRO) |
US20030068316A1 (en) | 1997-02-05 | 2003-04-10 | Klein William L. | Anti-ADDL antibodies and uses thereof |
US20060178302A1 (en) * | 1997-02-05 | 2006-08-10 | Northwestern University & The University Of Southern California | Amyloid beta protein (globular assembly and uses thereof) |
US6218506B1 (en) * | 1997-02-05 | 2001-04-17 | Northwestern University | Amyloid β protein (globular assembly and uses thereof) |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
EP1033998B1 (en) | 1997-12-03 | 2005-10-19 | Neuralab, Ltd. | Suppressing beta-amyloid-related changes in alzheimer's disease |
US6110502A (en) * | 1998-02-19 | 2000-08-29 | Mcneil-Ppc, Inc. | Method for producing water dispersible sterol formulations |
AU2486900A (en) | 1998-12-29 | 2000-07-31 | University Of Georgia Research Foundation, Inc., The | Rubredoxin fusion proteins, protein expression system and methods |
US6670195B1 (en) | 1999-05-26 | 2003-12-30 | New York University | Mutant genes in Familial British Dementia and Familial Danish Dementia |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
PE20010212A1 (en) | 1999-06-01 | 2001-02-22 | Neuralab Ltd | COMPOSITIONS OF THE A-BETA PEPTIDE AND PROCESSES TO PRODUCE THEM |
WO2001010900A2 (en) | 1999-08-04 | 2001-02-15 | University Of Southern California | Globular assembly of amyloid beta protein and uses thereof |
KR20080059676A (en) | 1999-11-29 | 2008-06-30 | 뉴로겜 인터내셔널 리미티드 | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
PT1284998E (en) | 2000-05-22 | 2005-06-30 | Univ New York | SYNTHETIC, NON-AMYLOOGOGENIC IMMUNOGENIC EPIDEMICS BETA-AMYLOID HOMOLOGISTS, INTENDED TO INDUCE AN IMMUNITY REACTION AGAINST BETA-AMYLOIDS AND AMYLOID DEPOSITS |
WO2002003911A2 (en) * | 2000-07-07 | 2002-01-17 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
US20030187011A1 (en) * | 2001-12-20 | 2003-10-02 | Lashuel Hilal A. | Apomorphine inhibitors of amyloid-beta (Abeta) fibril formation and their use in amyloidosis based disease |
PL209696B1 (en) * | 2002-04-19 | 2011-10-31 | Univ Toronto | Immunological methods and compositions for the treatment of alzheimer's disease |
US20040049134A1 (en) * | 2002-07-02 | 2004-03-11 | Tosaya Carol A. | System and methods for treatment of alzheimer's and other deposition-related disorders of the brain |
EP1578361B1 (en) * | 2002-09-12 | 2011-04-20 | The Regents of The University of California | Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence |
WO2005025516A2 (en) * | 2003-09-12 | 2005-03-24 | The Regents Of The University Of California | Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates |
WO2004031400A2 (en) | 2002-10-01 | 2004-04-15 | Northwestern University | Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof |
CA2504870A1 (en) * | 2002-11-04 | 2004-05-21 | Bioarctic Neuroscience Ab | Methods for the identification of agents that modulate the structure and processing of beta-amyloid precursor protein |
DE10303974A1 (en) * | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid β (1-42) oligomers, process for their preparation and their use |
US20050124016A1 (en) * | 2003-08-01 | 2005-06-09 | Enh Research Institute | Antibodies specific for toxic amyloid beta protein oligomers |
EP1668369B1 (en) | 2003-08-20 | 2016-01-06 | ProMIS Neurosciences Inc. | Epitope protection assay and method for detecting protein conformations |
SE0400707D0 (en) | 2004-03-22 | 2004-03-22 | Bioarctic Neuroscience Ab | Transgenic animal model |
SE0401601D0 (en) * | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
CA2572602A1 (en) | 2004-07-02 | 2006-02-09 | Northwestern University | Monolocal antibodies that target pathological assemblies of amyloid .beta. (abeta) |
US20060079447A1 (en) * | 2004-10-08 | 2006-04-13 | Wetzel Ronald B | Stabilized A-beta protofibrillar aggregates |
WO2006047254A1 (en) | 2004-10-22 | 2006-05-04 | Regents Of The University Of Minnesota | Assemblies of oligomeric amyloid beta protein and uses thereof |
JP5173426B2 (en) * | 2004-10-25 | 2013-04-03 | メルク・シャープ・エンド・ドーム・コーポレイション | Anti-ADDL antibodies and uses thereof |
US20060240486A1 (en) * | 2004-12-15 | 2006-10-26 | Johnson-Wood Kelly L | Immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies |
EP1853299A4 (en) | 2005-01-14 | 2009-11-11 | Univ California | Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders |
GT200600031A (en) * | 2005-01-28 | 2006-08-29 | ANTI-BETA ANTIBODY FORMULATION | |
US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
US7731962B2 (en) * | 2005-02-14 | 2010-06-08 | Merck & Co., Inc. | Anti-ADDL monoclonal antibody and use thereof |
EP1861422B1 (en) | 2005-03-05 | 2010-02-24 | Abbott GmbH & Co. KG | Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies |
US7741448B2 (en) | 2005-06-21 | 2010-06-22 | Medical & Biological Laboratories Co., Ltd. | Antibody having inhibitory effect on amyloid fibril formation |
TW200726774A (en) | 2005-06-30 | 2007-07-16 | Merck & Co Inc | Composition and method for producing stable amyloid beta oligomers |
TW200726482A (en) | 2005-06-30 | 2007-07-16 | Merck & Co Inc | Method for preparing a covalently cross linked oligomer of amyloid beta peptides |
RU2008120027A (en) | 2005-10-21 | 2009-11-27 | Мерк энд Ко., Инк. (US) | ANTI-ADDL MONOCLONAL ANTIBODY AND ITS APPLICATION |
CA2630964A1 (en) | 2005-11-22 | 2007-05-31 | The Trustees Of The University Of Pennsylvania | Antibody treatment of alzheimer's and related diseases |
WO2007108756A1 (en) | 2006-03-23 | 2007-09-27 | Bioarctic Neuroscience Ab | Improved protofibril selective antibodies and the use thereof |
MY158903A (en) | 2007-11-16 | 2016-11-30 | Univ Rockefeller | Antibodies specific for the protofibril form of beta-amyloid protein |
CA2765602C (en) | 2009-06-29 | 2021-05-25 | Bioarctic Neuroscience Ab | N-terminal truncated protofibrils/oligomers for use in therapeutic and diagnostic methods for alzheimer's disease and related disorders |
-
2004
- 2004-06-21 SE SE0401601A patent/SE0401601D0/en unknown
-
2005
- 2005-06-21 HU HUE05753672A patent/HUE025628T2/en unknown
- 2005-06-21 EP EP05753672.4A patent/EP1781703B1/en not_active Revoked
- 2005-06-21 PT PT57536724T patent/PT1781703E/en unknown
- 2005-06-21 SI SI200531986T patent/SI1781703T1/en unknown
- 2005-06-21 CA CA2570130A patent/CA2570130C/en active Active
- 2005-06-21 ES ES05753672.4T patent/ES2537001T3/en active Active
- 2005-06-21 US US11/570,995 patent/US8106164B2/en active Active
- 2005-06-21 DK DK05753672.4T patent/DK1781703T3/en active
- 2005-06-21 AU AU2005254928A patent/AU2005254928B2/en active Active
- 2005-06-21 WO PCT/SE2005/000993 patent/WO2005123775A1/en active Application Filing
- 2005-06-21 PL PL05753672T patent/PL1781703T3/en unknown
-
2011
- 2011-12-23 US US13/336,520 patent/US8404459B2/en active Active
-
2013
- 2013-02-28 US US13/780,643 patent/US8999936B2/en active Active
-
2015
- 2015-02-20 US US14/627,161 patent/US20150307601A1/en not_active Abandoned
- 2015-08-03 CY CY20151100678T patent/CY1116776T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
DK1781703T3 (en) | 2015-06-01 |
HUE025628T2 (en) | 2016-04-28 |
US20090155246A1 (en) | 2009-06-18 |
US20120230912A1 (en) | 2012-09-13 |
US20130236452A1 (en) | 2013-09-12 |
US8404459B2 (en) | 2013-03-26 |
WO2005123775A1 (en) | 2005-12-29 |
PT1781703E (en) | 2015-08-24 |
US8106164B2 (en) | 2012-01-31 |
AU2005254928A1 (en) | 2005-12-29 |
SE0401601D0 (en) | 2004-06-21 |
EP1781703B1 (en) | 2015-05-06 |
PL1781703T3 (en) | 2015-10-30 |
ES2537001T3 (en) | 2015-06-01 |
CA2570130A1 (en) | 2005-12-29 |
EP1781703A1 (en) | 2007-05-09 |
US20150307601A1 (en) | 2015-10-29 |
US8999936B2 (en) | 2015-04-07 |
SI1781703T1 (en) | 2015-08-31 |
AU2005254928B2 (en) | 2011-11-10 |
CY1116776T1 (en) | 2017-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2570130C (en) | Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof | |
US10538581B2 (en) | Anti-Aβ globulomer 4D10 antibodies | |
DK1976877T4 (en) | Monoclonal antibodies to amyloid beta protein and uses thereof | |
EP1881008B1 (en) | Method for the in vitro diagnosis of alzheimer's disease using a monoclonal antibody | |
US20130150560A1 (en) | AMYLOID BETA-DERIVED DIFFUSIBLE LIGANDS (ADDLs), ADDL-SURROGATES, ADDL-BINDING MOLECULES, AND USES THEREOF | |
WO2008067464A9 (en) | NEW Aβ CONFORMER SELECTIVE ANTI-Aβ GLOBULOMER MONOCLONAL ANTIBODIES | |
US8445649B2 (en) | Antibody and use thereof | |
KR20100046168A (en) | High sensitivty immunoassays and kits for the determination of peptides and proteins of biological interest | |
JP7151985B2 (en) | Anti-propanoylated amyloid β protein antibody | |
JP7221510B2 (en) | Propanoylation Modification Site-Specific Method for Amyloid β Protein | |
DK2289909T3 (en) | The screening method, method of purification of non-diffusing alpha-beta oligomers selective antibodies to said non-diffunderingsdygtige alpha-beta oligomers and a method of producing said antibodies | |
AU2017232091A1 (en) | Monoclonal antibodies against amyloid beta protein and uses thereof | |
Rutgers | Rutgers, KS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |